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1. Introduction
Infections of viral and bacterial origin are believed to cause exacerbations in 
patients with asthma.1 Most guidelines support the opinion that vaccination 
against influenza should be given to patients with asthma, including children.2, 3 
However, the proportion of children and adolescents with asthma that is 
vaccinated varies widely and is lower than that in the elderly.4 Fear of possible 
adverse reactions is one reason why patients are not given influenza vaccination as 
well as doubts about benefits and effectiveness of influenza vaccination amongst 
physicians and patients.5, 6 Inhalation medication for relief and maintenance 
therapy has made it easier to control asthma and exacerbations can be prevented 
or suppressed.7 A systematic Cochrane review of randomised controlled trials 
concluded that there is at the moment not enough evidence to assess the benefits 
and risks of influenza vaccination for people with asthma.8 Thus, proof whether 
influenza vaccination exacerbates asthma as an adverse effect as well as direct 
proof of a protective effect on exacerbations in asthmatic patients is needed to 
resolve the doubts posed by this review. 
Aim of this thesis is to provide evidence to either support or modify the policy 
of vaccinating asthmatic patients as is described in most western guidelines.2, 3 
I will focus on children, because in children asthma is the most important reason 
for influenza vaccination9 and asthma is the most frequent chronic disease in 
childhood. 
In chapter 2 I review what is known about the incidence of influenza in children 
aged 0-19 years. I performed a systematic review of the literature on this subject, 
restricting myself to studies that focussed on laboratory confirmed influenza related 
illness, thus providing the best available evidence for the impact of influenza and 
influenza related illness in children with and without asthma.
Chapter 3 deals with the question whether influenza vaccination itself may 
exacerbate asthma, an often expressed fear. To investigate whether this fear is 
justified, I report on respiratory symptoms during the first week after vaccination 
of our placebo-controlled trial. I also present data on other possible side-effects 
during this period.
Chapter 4 describes the main results of a randomised placebo-controlled trial that 
was designed to measure the effectiveness of influenza vaccination in preventing 
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asthma exacerbations in children with asthma. This is the first randomised placebo-
controlled trial in children that took influenza confirmed asthma exacerbations as 
and endpoint. Almost 700 children were recruited in general practices in greater 
Rotterdam who participated during either season 1999-2000 or 2000-2001.
In order to measure quality of life in children with asthma we needed an 
appropriate questionnaire. Chapter 5 describes the cross-cultural validation 
of the Dutch Pediatric Asthma Quality of Life Questionnaire (PAQLQ). This 
questionnaire, originally designed in the English language by Juniper,10 is regarded 
an important asthma specific quality of life questionnaire in children11 and has 
also been validated in a Spanish12 and Swedish version.13 It was translated into 
Dutch by Grol et al under supervision of Juniper.14 Psychometric properties, 
responsiveness, and longitudinal and cross-sectional construct validity of the 
Dutch version of this 23-item PAQLQ were assessed.
Chapter 6 outlines the effect of influenza vaccination on various secondary 
outcome measures, i.e. quality of life as measured by PAQLQ, spirometry and 
respiratory symptomatology. 
In chapter 7 the available knowledge on the burden of disease caused by influenza 
is debated, the absence of a universal definition of an “asthma exacerbation” is 
sketched and the results of our study given the current evidence on effectiveness 
of influenza vaccination in asthmatic children are discussed. Proposals are made 
to incorporate our findings in guidelines on influenza vaccination in asthmatic 
children. Finally, I offer some suggestions for future research into influenza, 
influenza related illness and influenza vaccination. 
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2.  Incidence of influenza and associated 
illness in children 0-19 years:  
a systematic review 
Abstract
Information on the incidence and burden of a disease and its natural course is a 
prerequisite to reliably forecast the impact of preventive measures. Similarly, such 
data are needed to estimate the number of participants required for experimental 
trials. For influenza these figures are not easily available.
Therefore, we conducted a systematic review to estimate the incidence of influenza 
and concomitant morbidity and mortality in children 0 through 19 years (0-19 
years). Medline was searched for observational studies and placebo or non-treated 
arms of experimental studies providing occurrence rates of laboratory-proven 
influenza illness.
From the 2758 titles identified, 356 full papers were reviewed based on the 
abstract or title; after searching their reference lists an additional 16 papers were 
found. Finally 28 studies met our inclusion criteria, reporting a varying seasonal 
incidence of influenza of up to 46%. However, when analysing two long-term 
observational studies and averaging seasonal fluctuations, the overall incidence 
of influenza was found to range from 5 to 9.5% per year. Serious morbidity was 
seldom reported and no cases of mortality were found.
Given the average incidence, the self-limiting character of the disease, the mild 
associated morbidity and rare cases of mortality in children, one can question 
whether influenza in children in western countries at the population level is a 
major public health problem.
We conclude therefore that preventive strategies for children should be reconsidered. 
When studying influenza one should be led by the average incidence and include 
more influenza seasons.
 
Introduction
Influenza is a common respiratory tract infection in children1, 2 and, according 
to the WHO, a yearly public health problem in children and in the community 
at large.3 Based on its occurrence and a rise in influenza-like illnesses, influenza 
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centres worldwide provide information on its activity and presumed impact.4 
Many viruses, however, can be responsible for influenza-like illness5-7 and the 
true incidence of influenza proper and its associated illness remains unclear. This 
implies that the advice of policymakers and public health authorities worldwide 
to vaccinate children with chronic health conditions (mainly asthma)8-10 and, more 
recently, healthy children under two years of age,11, 12 is based on a subjective 
assessment of indirect evidence. For influenza proper, laboratory proof of its 
causal viruses should preferably coincide with symptomatic disease.13 However, 
in reports on the impact of influenza outbreaks, proxy measures are used, such 
as isolated serologic incidence rates, rates of influenza-like illness1, 4, 14-17 and 
complications.18-21 In these studies, however, hard confirmation of ‘influenza 
illness’ is lacking on the individual level and, moreover, reports on the disease 
burden of influenza (e.g. hospitalisations) are often not related to a well defined 
population at risk for influenza.
We became aware of this lack of hard data when we recently conducted a double-
blind placebo-controlled trial on the effectiveness of influenza vaccination in 
asthmatic children.22 When looking for data on incidence and disease burden 
related to influenza for our power calculations, we found out that these were 
scarce, showed a wide variation, and were of mixed quality.
With hindsight we concluded that before reasonable forecasts can be made about 
the need and cost effectiveness of preventive and curative measures for influenza 
in children, several questions about its natural course need to be addressed:
(1)  What is the incidence of laboratory-proven influenza in children  
(aged 0-19 years)?
(2)  What are the symptoms or illnesses that give rise to confirmatory 
laboratory tests? 
(3)  What is the related severity and duration of illness in fully confirmed 
cases? 
(4)  What is the nature and frequency of complications reported in these 
patients? 
(5) What is the related health care use of these patients?
To answer the first two questions we performed a systematic review of community-
based epidemiological studies to investigate and assess the available data on the 
incidence of laboratory proven influenza in children 0-19 years. Additionally, we 
searched for data from non-treated or placebo treated arms of clinical trials on 
influenza vaccination or influenza treatment.
To answer the remaining questions the included studies were systematically 
reviewed for relevant data on severity, complications, and healthcare use.
21
Material and methods
Studies were identified by a Medline database search from inception to October 
2003. For the detection of studies on the epidemiology of influenza we used as 
search items “influenza/epidemiology OR influenza/mortality”. For clinical trials 
studying treatment and prevention of influenza we adapted the search strategy 
as described by Dickersin et al.23 Using the ‘Limits’ option in Medline we limited 
searches to children (0 through 18 years), human subjects, and papers in English, 
German, French, and Dutch. Additional strategies for identifying studies included 
searching the reference lists of review articles and of included studies.
Study selection
Based on the search results, one of the authors (HJB) selected papers on the basis 
of title and abstracts. Abstracts were screened for clues of data of a prospective 
study on the incidence of influenza in children. If the screening was positive, or 
in case of doubt, full papers were obtained. Three of the authors (HJB, MYB, 
and JCvDW) checked these selected studies in couples of two reviewers.
Apart from studies including children recruited from the open community, we 
included studies in children residing in an institution, e.g. boarding schools and 
day care centres. In studies that also included larger age ranges, data concerning 
the age category 0-19 years were extracted whenever possible.
Quality assessment
We developed five quality criteria. (1) The study had to be prospective, that is 
either report on a longitudinal cohort or a dynamic population, or on placebo 
or non-treated arms of experimental studies. (2) The numerator of the study 
population should consist of cases of influenza illness proven by laboratory tests. 
(3) Laboratory methods should be performed in at least 75% of the participants 
with symptoms or illness. (3) The denominator should consist of a population 
of at least 30 children at risk for influenza followed over a specified time period. 
(4) The population at risk should not be pre-selected on the basis of symptoms of 
influenza-like illness, because this would invalidate the calculation of population-
based incidence rates. (5) Laboratory methods were culture, antigen detection 
or PCR from material taken from nose or throat, or serology from paired acute 
and convalescent blood samples. Studies were included if they fulfilled all five 
quality criteria. 
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If in a reported period of illness tests were positive for influenza we attributed 
this illness to influenza infection. 
The authors (HJB, MYB, and JCvDW) independently rated the methodological 
quality of all selected studies in couples of two reviewers. If necessary, reviewers 
discussed papers to reach consensus on inclusion. When consensus was not 
reached by a couple the opinion of the third reviewer was decisive. 
Data extraction
Data extraction and synthesis were performed by one of the authors (HJB) and 
verified by another author (JCvDW). If available we extracted information (using 
a structured form) on demographics, in- and exclusion criteria, a description of 
the study population, and occurrence of influenza.
For cohorts the incidence of influenza and illness is represented per influenza 
season or part of the season as reported, for dynamic populations (i.e. dropouts 
are replaced) we assumed the incidence per year to be equal to the incidence per 
influenza season.
Results
The search revealed 2758 studies after correction for duplicates; of these 356 
were selected for reviewing. The references of these papers yielded 16 additional 
papers. Of these 372 papers meeting our inclusion criteria, the process of reviewing 
resulted in 28 studies. 
Of the 342 rejected studies, 314 were excluded because influenza-like illness was 
not confirmed by laboratory testing or because the population at risk was pre-
selected (e.g. consisting of only children with fever), or a combination of these 
items. Sixteen studies were excluded because laboratory tests were taken in less 
than 75% of the cases in the population at risk or the population consisted of 
less than 30 participants, 5 studies repeated findings from original and already 
included reports, and 7 were excluded for various other reasons.
There was a vast heterogeneity between studies regarding the span of time 
studied, laboratory methods used, criteria for performing laboratory tests, types 
of population and (knowledge of) vaccination status. Due to this heterogeneity 
we decided not to pool data between studies. To gain an overview, we did pool 
age categories within the studies if these data were collected over the same time 
period. When studies themselves pooled data for more influenza seasons, we 
provide these data. When studies report influenza incidence per influenza season 
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or time period we present these data and also a weighted average in case of more 
than one period.
Data on the incidence of influenza in children aged 0-19 years are presented in 
Table 1; rates of influenza are given in percentages. As can be seen, the incidence 
found (in observational studies and in non-vaccinated participants of controlled 
clinical trials) varies widely from season to season, both for influenza A and B. 
Furthermore, a wide variety of index populations was studied. Some studies used 
an open setting, recruiting children from the general population or from different 
households, whereas other studies addressed more closed populations such as 
primary schools, day care centres, boarding schools or residential institutions. 
Research periods ranged from a few weeks to as long as 25 years.
The reported incidence of influenza in children varied in all age categories, and 
ranged from 0 to 46% [table 1]. However, in the two studies that reported the 
incidence of influenza over a prolonged time period, the average seasonal incidence 
was 4.6% in children aged 0-19 years and 9.5% in children <5 years.16, 24
In all studies the triggers to search for laboratory confirmation of influenza 
were local tract symptoms or systemic symptoms, mainly respiratory tract 
symptoms and fever. Two studies took laboratory samples when children 
where hospitalised for respiratory symptoms.25, 26 Only a few of the studies 
provided extensive information on the course, duration and severity of disease or 
subsequent morbidity and complications.16,  24,  27 Symptoms triggering laboratory 
confirmation and symptoms described in the course of episodes of illness were 
usually characterised as mild. Mortality as an outcome of influenza illness was 
not found in any of the selected studies.
We provide a broad summary of illness and subsequent morbidity reported 
to be influenza related in the selected papers. We report both general remarks 
made by authors as well as remarks on an influenza specified laboratory-proven 
sample of the observed population. Because of our inclusion criterion of proven 
influenza, for some articles only a part of the population was included in this 
review. However, remarks of authors on disease were often only related to the 
broader definition used in their study. In case remarks relate to our more narrow 
selection, we also provide the number of children concerned.
Moffet et al. reported that the most prominent signs were fever and absence 
of localizing symptoms. Complications were uncommon and not severe or life 
threatening. Clinical recovery was rapid. In two out of 280 children there was 
radiological evidence of pneumonia but no child was severely ill, otitis media 
was diagnosed four times and sinusitis three times.28 Pereira et al. reported that 
in 262 children, 4 out of 6 influenza cases had only mild nasal symptoms and 
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noted school absence of two days in only one case.29 Weibel et al. reported that 
6 of 12 children with influenza B (from a total of 208), had severe respiratory 
illness, i.e. respiratory symptoms combined with fever above 102 °F.30 Sanders 
et al. found an average duration of three days of illness, and in 1.4% of 280 
participants pneumonitis was documented by X-ray.27 Hoskins et al. reported 
usually mild illnesses.31 In a 25-year study in children 0-5 years, Neuzil et al. 
reported that rates of acute otitis media and lower respiratory tract infections 
caused by influenza were higher in children under 2 years of age.24 Of an annual 
average of 123 children over 25 years, 8 were diagnosed as having croup, 7 
pneumonia, 6 bronchiolitis, 3 tracheobronchitis and 2 epiglottitis. Seven children 
(all aged <2 years) were hospitalised with fever, a hospitalisation rate of 230 per 
100,000; they were diagnosed as having meningitis (2), croup (2), pneumonia 
(1), periorbital cellulitis (1), and sepsis (1), and in three hospitalised children a 
bacterial super-infection was present. Duration of hospitalisation ranged from 
1-10 days. Taber et al. described uncomplicated upper respiratory illness and 
three hospitalisations in younger children out of 88 children 0-19 years of age, 
a hospitalisation rate of 3.4%.32 Frank et al. reported that 77% of illnesses of 
children were febrile, influenza-like or lower respiratory illness, and one 18 month-
old boy was hospitalised with a febrile seizure and evidence of pneumonia.33 
Monto et al. observed (in 466 children and with an incidence of 4.6% over 5 
years) for H3N2, H1N1 and B respectively, lower respiratory tract illness in 12, 
13 and 15% of cases, fever in 84, 64 and 71% of cases, physician consultation 
in 54, 26 and 44% of cases, and a median duration of the illness of 12.7 days 
for influenza A and 10 days for influenza B.16 Wright et al. found “impressive 
illness”, mainly fever and respiratory infections, caused by H3N2 and less illness 
by H1N1.34 Foy et al. reported “deceptively mild symptoms” which could easily 
be confused with common colds.35 Gruber et al. found an incidence of 26% in 
77 children and recorded in 35% illness (otitis media and tracheobronchitis) 
and in 31% fever in reported cases of influenza.36 Heikkinen et al. found that 29 
(67%) out of 187 children with influenza A suffered from otitis media whereas 
Belshe et al. reported percentages for otitis media of 46 and 30 in about 16% of 
973 children infected.37-39 Gruber et al. reported fever and otitis media in 14% 
of 19 affected children out of a total of 88.40 Sugaya et al. reported that 60% of 
12 affected children (out of a total of 52) had febrile influenza illness and found 
three hospitalisations for pneumonia with influenza B, a hospitalisation rate of 
almost 6%.41 Mizuta et al. described fever, headache, sore throat, cough and 
nasal discharge in 13 cases out of 165 children.42 
We detected two studies that provided prospective data on the incidence of 
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influenza if hospitalisation for respiratory symptoms due to influenza was regarded 
and, because this trigger for taking laboratory tests is different from the other 
studies, we report these separately [table 2]. Additionally, we present data on 
hospitalisation that were reported in a long term study by Neuzil et al.24 and that 
could be calculated from two small studies by Taber et al.32 and Sugaya et al.41 
Incidence rates of hospitalisation due to influenza range from 8 to 5769 admissions 
per 100,000 children at risk per year. Caul et al. reported complementary data 
on morbidity, i.e. convulsions with or without respiratory illness were in 36% 
the reason for admission in the presence of influenza, especially in those aged 1-2 
years. Furthermore, upper respiratory infections were in 43% of influenza cases, 
croup in 7%, bronchitis in 19%, bronchiolitis in 11%, pneumonia in 11% and 
convulsions alone in 15% the reason for hospital admission.25 
table 2.  incidence of hospital admission for influenza-proven 
respiratory symptoms. figures per 100,000 children at risk 
per time period 
Ref. Population characteristics   Incidence$
 Population Time periods Age Vaccination* A B
Martin26 adherent epidemic periods <16 yrs nm 32
 based on 1971-1972
 census epidemic periods   25
 approximately 1972-1973
 150,000 epidemic periods   8
  1973-1974
  epidemic periods   28
  1974-1975
  epidemic periods   52
  1975-1976
Caul25 adherent# Nov 1973- 0-4 yrs nm 59 7
  59311 March 1975
Taber32  88 Jan-April 1976 0-19 yrs nm 3409
Sugaya41  52 Dec 1992-Feb 1993 2-14 yrs none 5769
Neuzil24  123# Aug 1974-July 1999 0-5 yrs nm 230
 $  In given time period, in case the time period encompasses more than one year 
  the incidence is calculated and averaged per year
 * nm = not mentioned      # Average annual number in surveillance
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Discussion
We found a wide variation in incidence data on influenza and influenza-proven 
illnesses in children aged 0-19 years. Of course year, place and composition of 
the population all may have an important impact on the incidence of influenza 
and related illness. Furthermore, a considerable number of observational studies 
were motivated by an outburst of influenza in more or less closed populations 
and, therefore, provide a one-sided picture of the overall incidence. It is likely 
that years with no or little influenza activity were underrepresented. In addition, 
clinical trials are not designed to assess the incidence of overall illness for influenza, 
but will for obvious reasons focus on a certain degree of clinical illness by using 
a threshold before taking samples. Most of these biases will overestimate the 
true incidence of influenza.
With all these restrictions incidence of laboratory-proven influenza, coinciding with 
illness, ranged from 0 to 46% in the studies we included. When we consider the 
highest incidence rates for influenza and associated illness, health care utilisation 
probably would be considerable. In that case, the prevention of influenza could 
be extremely cost effective leading to considerable health benefits. However, a 
high incidence is mostly found in more closed populations and at outbursts of 
influenza, and this may distort the picture. As can be seen in studies in the open 
population, the incidence of influenza (averaged over several years of follow-up), 
is much lower, i.e. respectively 4.6% (0-19 years) and 9.5% (0-5 years).16, 24 The 
yearly average incidence of influenza and its related illness in these dynamic 
populations is probably the best estimate that policymakers, health authorities 
and researchers can rely on.
The impact of preventive measures for influenza will be less favourable if we 
also consider the reported subsequent morbidity and complications next to 
the symptom-based incidence of influenza. In most studies included, reported 
influenza-related illness was low, the morbidity pattern of influenza was mild, 
the number of hospital admissions was small, and no mortality due to influenza 
was reported.
Children younger than two years of age may need special attention, because 
we found that a relatively high incidence of influenza and most complications 
occurred in this age group.24 Reasons for protecting the younger age groups and 
chronic disease categories in children mainly come from large retrospective studies 
on hospitalisation, and the use of medication or consultation for respiratory 
tract infections during influenza seasons.18, 19 Neuzil et al. estimated (over a 
19-year period) an excess hospitalisation due to influenza-related disease of 
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40 to 1040 per 100,000 children (aged 0-15 years) at risk per year, declining 
with age.19 Izurieta et al. estimated over a 5-year study period a similar decline 
in excess hospitalisation of 1.5 to 19 per 100,000 children (aged 0-18 years) per 
year.18 Prospective figures as mentioned here in the census-based and long-term 
studies of between 29 and 230 hospitalisations for influenza per season or year 
per 100,000 children 0-16 years of age at risk24-26 are in line with the findings of 
Izurieta et al. and the lower boundaries of rates of hospitalisations as found by 
Neuzil et al. The much higher incidences of hospitalisation found by Taber et 
al. and Sugaya et al. will probably be less accurate due to the small numbers of 
participants and a limited time window, i.e. an outburst of influenza.32, 41
Influenza in children is a self-limiting disease. Hospital admissions due to influenza 
are rare. Based on the figures presented, H3N2 and B variants are found more 
frequently than H1N1. Illness due to H1N1 seems to be mild or absent.
Although our search of the literature has revealed specifically those studies that 
focus totally or in part on influenza it is, however, possible that studies on other 
topics (e.g. other viruses), containing information on the incidence of influenza 
and illness were missed. The incidence of infection with less severe symptoms 
or sub-clinical influenza can of course be higher. However, a mild course of the 
disease makes treatment less relevant. 
As most studies found were performed in developed countries with a well-
developed health care system, we cannot extrapolate our findings to the less 
developed countries.
Our findings on the varying incidence of influenza and the self-limiting character 
of most diseases caused by influenza in children do not support strategies 
proposing to vaccinate all healthy children year after year. The two studies in 
asthmatic children revealed no serious complications in this disease category.41, 43 
In closed populations incidence may be high but severe complications are, again, 
uncommon.
Over the years, doubts have been expressed about the protective effect of influenza 
vaccination in children for the prevention of clinical illness.22, 44-47 Moreover, the 
ever-changing antigenic appearance of the influenza virus and logistic problems 
surrounding the vaccine production make it difficult to produce a matching 
vaccine in adequate time. 
New antiviral treatments (e.g. the new neuraminidase inhibitors), may play a role 
in the prevention and treatment in non-pandemic influenza seasons in children. 
However, although clinical effectiveness has been established in healthy children, 
no efficacy was found in children with asthma,48 being the most important chronic 
condition for which vaccination is advised.49
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None of our findings strongly supports the necessity of extending preventive and 
curative health care in influenza seasons. A preparedness plan for children with 
influenza has to consider the unpredictable incidence of influenza and illness as a 
result of the infection, which over the years on average is low, and the self-limiting 
character of the disease in children. Therefore, it will be difficult to attain health 
benefits and cost effectiveness over the years.
When researching the incidence of influenza and its related illness, and determining 
the effect of preventive and curative measures, studies should cover several 
seasons. Also, when calculating the power for clinical trials one should take 
account of the reported overall averages of influenza incidence as found in long-
term observational studies, instead of isolated incidence rates. 
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Does influenza vaccination exacerbate 
asthma?
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3.  Does influenza vaccination  
exacerbate asthma?
Abstract
The risks of influenza vaccination in asthmatic children are still being discussed. 
Especially the risk that influenza vaccination may exacerbate asthma is an issue 
in this debate.
We conducted a randomised double-blind placebo-controlled trial in 696 children 
6-18 years of age with asthma recruited in general practice during two influenza 
seasons, 1999-2000 and 2000-2001. Children participated for only one season. 
During the first week after vaccination, participants recorded local, influenza 
like and asthma symptoms as well as use of medication, health care use and 
absenteeism.
Except for cough during the day in the first season, favouring placebo, there were 
no differences indicating that vaccination exacerbates asthma.
Influenza vaccination does not seem to exacerbate asthma.
Introduction
Because viral infections, including influenza, cause exacerbations in children with 
asthma,1, 2 vaccination of such children is recommended in most of Europe and 
North America.3 Fear of possible adverse reactions is one reason why patients 
are not given influenza vaccination4, 5 and in asthmatic children vaccination rates 
have been reported to be very low.6, 7 Although influenza vaccination has few 
adverse reactions it is uncertain whether it exacerbates asthma.8-13 We therefore 
performed a double blind placebo-controlled trial in asthmatic children and 
examined if influenza vaccination exacerbates asthma. We will report on asthma 
symptoms and other adverse reactions, i.e. local and influenza like symptoms in 
the first week after vaccination. We will also give an account of use of medication, 
health care use and absenteeism.
Methods
We conducted a randomised double blind placebo-controlled trial in children with 
asthma recruited in general practice during two seasons, 1999-2000 and 2000-
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2001. We recently reported the effects of vaccination on asthma exacerbations 
related to influenza infections.14
In this part of the study, we aim to answer the question if there is a difference in 
reported adverse reactions, especially asthma symptoms, between vaccine and 
placebo recipients.
Eligible were children aged 6-18 years who had used specific asthma medication: 
maintenance medication (inhaled corticosteroids, cromoglycate) or more than 
52 doses of relief medication (β-2-agonists, anticholinergics) for asthma the year 
previous to inclusion. Exclusion criteria were other chronic diseases, allergy to 
chicken protein and insufficient understanding of the Dutch language. In both 
seasons, research nurses vaccinated all participants between 25 October and 
24 November with either inactivated influenza vaccine or placebo. Every child 
participated for only one season. The vaccine composition for 1999-2000 was a 
combination of A/Sydney/5/97 (H3N2)-like, A/Beijing/262/95 (H1N1)-like and 
B/Beijing/184/93-like strains and for 2000-2001 A/Moscow/10/99 (H3N2)-like, 
A/New Caledonia/20/99 (H1N1)-like and B/Beijing/184/93-like strains as advised 
by the World Health Organisation. The placebo consisted of a buffered phosphate 
solution with the same pH value and was similar in appearance to the inactivated 
influenza vaccine. The manufacturer (Solvay Pharmaceutical Products, Weesp, 
the Netherlands) stored the vaccines after production at 2 to 8 °C. Vaccines were 
transported to and stored under optimal conditions at the central pharmacy of 
the University Hospital Rotterdam until shortly before vaccination.
Participants recorded symptoms of influenza like illness and asthma in a diary. 
Symptoms scored in the diaries during the first seven days after vaccination were 
considered to be adverse reactions of the vaccination. Additionally, we asked 
during these seven days for red or painful arm, use of medication, contact with 
a physician and absence from school or work for participants and their parents. 
If present, respiratory tract symptoms were scored from 1 (mild) to 3 (severe) 
and summated. Serious adverse reactions that were reported after the first week 
were scrutinised to assess their causal relation with the vaccination.
In the analysis, the frequencies of symptoms reported in the group of children 
that received vaccine were compared to those receiving placebo, in order to 
assess the magnitude of the proportion of symptoms that could be ascribed to 
the vaccine. Differences were tested by Pearson χ2 tests with continuity correction 
with one-sided p-values of 0.05 in case of categorical variables and with ANOVA 
for numerical data.
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Results
table 1. baseline characteristics of the study population (n=696)
  vaccine placebo
values are percentages unless otherwise stated n=347 n=349
age in years, mean (SD) 10.5 (3.2) 10.6 (3.3)
child born in the Netherlands 97.7 98.9
female sex 48.1 43.6
age of onset of asthma in years, mean (SD) 3.5 (3.8) 3.3 (3.4)
asthma complaints more than once a week in previous 12 months 15.6 18.6
only maintenance medication in previous 12 months 29.1 24.4
relief and maintenance medication in previous 12 months 59.9 64.8
FEV1-% predicted, mean (SD) 89.5 (16.1) 88.9 (16.0)
ever treated by asthma specialist 40.7 46.6
still treated by asthma specialist  25.9 27.1
ever hospitalised for asthma 16.2 17.0
vaccinated previous season for influenza 51.4 53.0
ever vaccinated for influenza 53.6 56.7
if vaccinated before, number of seasons, mean (SD) 2.9 (1.9) 2.8 (1.8)
history of allergy 73.5 66.1
proven allergy for pollen, house dust mite or pets 47.3 44.7
history of eczema 50.6 48.4
seasonal influence on asthma 74.4 77.0
family history of asthma 78.7 77.1
exposure to cigarette smoke at home 30.3 33.2
current smoker 2.6 2.6
pets at home 58.2 59.6
After inclusion and informed consent 696 children were randomised (first season 
296, second season 400). The groups were similar for baseline characteristics 
[table 1]. In the first season 148 children were vaccinated with influenza vaccine 
and 148 with placebo vaccine. In the second season 199 children were vaccinated 
with influenza vaccine and 201 with placebo. For adverse reactions, the proportion 
of missing data per item varied from 0% to 6%. Local symptoms (erythema 
and painful or stiff arm) were often reported, especially the first four days after 
vaccination [table 2]. The proportion of children reporting these two local 
symptoms the first seven days after vaccination was about three times as high 
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in the vaccine group as in the placebo group, with absolute differences of up to 
23% for erythema and up to 48% for stiffness or pain during the first days after 
vaccination. For influenza like symptoms, no consistent pattern was found [table 3]. 
Fever (8%), headache (10%) and myalgia (18%) were reported significantly 
more often in the vaccine group than in the placebo group during the first season, 
especially at days 4-6 after vaccination. During the second season, hoarseness 
showed a difference of 5% favouring the placebo group. For asthma symptoms, 
only the first season showed a difference of 12% (44% vs. 32%) in cough during 
daytime favouring placebo [table 4]. The severity of asthma symptoms, as 
measured by symptom scores, showed no difference between the groups.
The use of medication for airway symptoms, physician consultations, school 
absenteeism, and work absenteeism as well as the number of children that needed 
a child-minder as a consequence of the adverse reactions did not differ [table 5]. 
The mean number of doses of relief medication taken in the first week was 4.5 
per child in both groups.
In December 1999 a serious illness (mastocytosis) was reported by the parents of 
one of the participating children. Upon careful consideration of onset and course 
of illness, it was decided that a causal relationship with the study medication 
was highly unlikely. Afterwards, we established that this child had received 
placebo.
table 5.  medication use, consultation and absenteeism,  
days 1-7 after vaccination
 1999-2000 2000-2001
 vaccine placebo p-value vaccine placebo p-value
 (n=148) (n=148)  (n=199) (n=201)
medication for 
airway symptoms 67% 69% NS 68% 62% NS
medication use total 70% 71% NS 71% 65% NS
consultation of doctor 0% 1% NS 2% 1% NS
school absenteeism 6% 10% NS 5% 3% NS
work absenteeism 0% 0% NS 1% 1% NS
childminder needed 0% 0% NS 1% 0% NS
NS = not significant (p-value >0.05)
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Discussion
The most important finding in this trial is that, with exception of cough during 
daytime in the first season, no differences were found for the frequency and 
severity of asthma symptoms as an adverse reaction to vaccination. There were 
no differences in the use of relief medication. Fever, headache and myalgia showed 
small though significant differences during the first season, as did hoarseness 
during the second season. These differences may be an expression of the difference 
in strains used in the vaccine during the two seasons or can be a result of a 
difference in populations between the two influenza seasons. As reported in 
previous studies, vaccine recipients reported redness and stiffness of the arm 
much more often than placebo recipients.12, 15 
Our findings do not support previous conclusions in a systematic Cochrane 
review, which especially stated the risk of influenza vaccination to exacerbate 
asthma.13
A recent placebo-controlled crossover study of the American Lung Association 
Clinical Centers did not find any adverse reactions on asthma-related outcomes.12 
Other studies had prospective or retrospective designs without placebo, which 
are prone to various sources of bias and make comparison difficult.11, 16, 17 All 
previously mentioned studies recruited patients in secondary or tertiary care 
centres, whereas we recruited in general practice. A limitation of our study is 
that in comparison with other studies in asthmatic patients our study population 
may consist of less severe asthmatics, so our findings can not be extrapolated to 
all children in secondary or tertiary care. However, we only included children 
with moderate or severe asthma, that, according to national and international 
guidelines,3, 18 should all be vaccinated.
We found that influenza vaccination of children with asthma in general practice 
had no severe local or general adverse reactions in asthmatic children. No extra 
precautions have to be taken when vaccinating these children. If influenza 
vaccination for children with asthma is advised, strategies have to be developed 
and used to convince patients, parents and doctors of those facts. 
In conclusion, apart from mild adverse reactions, fear that influenza vaccination 
exacerbates asthma seems to be no valid reason to refrain from immunising 
asthmatic children with inactivated influenza vaccine.
45
References
1  Minor TE, Dick EC, DeMeo AN, et al. Viruses as precipitants of asthmatic attacks in 
children. JAMA 1974; 227: 292-8.
2  Johnston SL, Pattemore PK, Sanderson G, et al. Community study of role of viral 
infections in exacerbations of asthma in 9-11 year old children. BMJ 1995; 310:  
1225-9.
3  Nicholson KG, Snacken R, Palache AM, Fedson DS. Influenza immunization policies 
in Europe and the United States. Vaccine 1995; 13: 365-9.
4  Fiebach NH, Viscoli CM. Patient acceptance of influenza vaccination. Am J Med 
1991; 91: 393-400.
5  Nichol KL, Mac Donald R, Hauge M. Factors associated with influenza and 
pneumococcal vaccination behavior among high-risk adults. J Gen Intern Med 1996; 
11: 673-7.
6  Szilagyi PG, Rodewald LE. Missed opportunities for influenza vaccination among 
children with asthma. Pediatr Infect Dis J 1992; 11: 705-8.
7  Kramarz P, DeStefano F, Gargiullo PM, Storms W. Influenza vaccination in children 
with asthma in health maintenance organizations. Vaccine Safety Datalink Team. 
Vaccine 2000; 18: 2288-94.
8  McIntosh K, Foy H, Modlin JF, et al. Multicenter two-dose trials of bivalent influenza 
A vaccines in asthmatic children aged six to 18 years. J Infect Dis 1977; 136: S645-7.
9  Park CL, Frank A. Does influenza vaccination exacerbate asthma? Drug Saf 1998;  
19: 83-8.
10  Nicholson KG, Nguyen-Van-Tam JS, Ahmed AH, et al. Randomised placebo-
controlled crossover trial on effect of inactivated influenza vaccine on pulmonary 
function in asthma. Lancet 1998; 351: 326-31.
11  Kramarz P, DeStefano F, Gargiullo PM, et al. Does influenza vaccination exacerbate 
asthma? Analysis of a large cohort of children with asthma. Vaccine Safety Datalink 
Team. Arch Fam Med 2000; 9: 617-23.
12  The American Lung Association Asthma Clinical Centers. The safety of inactivated 
influenza vaccine in adults and children with asthma. N Engl J Med 2001; 345: 1529-
36.
13  Cates CJ, Jefferson TO, Bara AI, Rowe BH. Vaccines for preventing influenza in 
people with asthma (Cochrane Review). Oxford: Update Software, 2002.
14  Bueving HJ, Bernsen RM, de Jongste JC, et al. Influenza vaccination in children with 
asthma: randomized double-blind placebo-controlled trial. Am J Respir Crit Care 
Med 2004; 169: 488-93.
46
15  Edwards KM, Dupont WD, Westrich MK, et al. A randomized controlled trial of cold-
adapted and inactivated vaccines for the prevention of influenza A disease. J Infect 
Dis 1994; 169: 68-76.
16  Hilman BC, Jamison RM, Kirkpatrick CJ. Reactivity and antibody response to 
vaccination with bivalent influenza A/Victoria/75-A/New Jersey/76 vaccines in 
children with chronic pulmonary diseases. J Infect Dis 1977; 136: S638-44.
17  Gruber WC, Taber LH, Glezen WP, et al. Live attenuated and inactivated influenza 
vaccine in school-age children. Am J Dis Child 1990; 144: 595-600.
18  G.A. van Essen, Sorgedrager YCG, G.W. Salemink, et al. NHG-Standaard Influenza 
en influenzavaccinatie [NHG-standard influenza and influenza vaccination], Huisarts 
Wet. 1996; 39: 564.
  
 
47
Chapter 4a
Influenza vaccination in children with 
asthma: randomised double-blind  
placebo-controlled trial
American Journal of Respiratory and Critical Care 
Medicine 2004; 169: 488-93.
Bueving HJ, Bernsen RMD, de Jongste JC,  
van Suijlekom-Smit LWA, Rimmelzwaan GF,  
Osterhaus ADME, Rutten-van Mölken MPMH, 
Thomas S, van der Wouden JC.
 
48
49
4a.  Influenza vaccination in children with 
asthma: randomised double-blind 
placebo-controlled trial
Abstract
There is little evidence that influenza vaccination reduces asthma exacerbations. 
We determined whether influenza vaccination is more effective than placebo in 
asthmatic children 6-18 years of age. 
We performed a randomised double-blind placebo-controlled trial. Parenteral 
vaccination with inactivated influenza vaccine or placebo took place between 
25 October and 24 November and children were followed until April 1st of the 
next year. Airway symptoms were reported in a diary. When symptom scores 
reached a predefined level, a pharyngeal swab was taken. Primary outcome 
was the number of asthma exacerbations associated with virologically proven 
influenza infection. 
Three hundred forty-nine children were assigned placebo and 347 were assigned 
vaccine. Pharyngeal swabs positive for influenza were related to 42 asthma 
exacerbations, 24 in the vaccine group and 18 in the placebo group, a difference 
of 33% favouring placebo (31% after adjustment for confounders, 95%CI -34% 
to 161%). Influenza-related asthma exacerbations were of similar severity in 
both groups, they lasted 3.1 days shorter in the vaccine group (95%CI -6.2 to 
0.002 days, p=0.06). 
We conclude that influenza vaccination did not result in a significant reduction 
of the number, severity or duration of asthma exacerbations caused by influenza. 
Additional studies are warranted to justify routine influenza vaccination of 
asthmatic children.
Introduction 
Infections of viral origin, including influenza, cause exacerbations in patients 
with asthma.1, 2 Most guidelines support the opinion that influenza vaccination 
should be given to patients with asthma, including children.3
Over the years the necessity of vaccinating patients with asthma has been 
discussed.4-6 A Cochrane systematic review on influenza vaccination in people 
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with asthma concludes that, because of the lack of randomised trials, the evidence 
to assess the benefits and risks of influenza vaccination is insufficient.7 Inhalation 
medication for relief and maintenance therapy has made it easier to control 
asthma and exacerbations can be prevented or suppressed, so patients can lead 
a normal life. 
The proportion of children with asthma that is vaccinated varies widely and is 
lower than in the elderly.8 This is partly due to doubts amongst patients and 
doctors about the benefit of the vaccination and lack of evidence for the protective 
effect of influenza vaccination against asthma exacerbations.9, 10
An answer to the question whether influenza vaccination can prevent exacerbations 
in asthmatic children is necessary to either validate or modify current guidelines 
and may enhance evidence-based practice.
We conducted a study to investigate whether influenza vaccination in asthmatic 
children prevents asthma exacerbations provoked by influenza infection. Some 
of the results of this study have been previously published in the form of 
abstracts.11-13
Methods
Participants
We performed a randomised double-blind placebo-controlled parallel trial in 
children 6-18 years of age with asthma, recruited through family physicians in 
the city of Rotterdam and its surroundings, during the winter seasons of 1999-
2000 and 2000-2001. Patients could only participate for one season. Exclusion 
criteria were other chronic diseases, allergy to chicken protein and insufficient 
understanding of the Dutch language. See chapter 4b (additional methods and 
results) for further details. We informed parents and children orally and in written 
text about the purpose and contents of the study and obtained informed consent 
for those willing to participate. The Medical Ethical Committee of Erasmus MC 
- University Medical Center Rotterdam approved the study.
Interventions
In both seasons, research nurses vaccinated all participants between 25 October 
and 24 November with either inactivated influenza vaccine or placebo. Vaccine 
details are provided in chapter 4b (additional methods and results). 
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Objectives
We aimed to answer the question whether influenza vaccination is more effective 
than placebo in preventing asthma exacerbations caused by influenza infections 
among asthmatic children 6-18 years of age. We tested the null hypothesis that 
placebo is as effective as influenza vaccination in preventing asthma exacerbations 
caused by influenza infections. 
Outcomes
Primary outcome was the number of asthma exacerbations associated with 
virologically proven influenza infection. Secondary outcomes were amongst 
others the duration and severity of these asthma exacerbations, adverse effects 
of the vaccination including airway symptoms, the number, duration and severity 
of all asthma exacerbations, and of influenza-related and all upper respiratory 
tract (URT) episodes. Additional outcomes are listed in chapter 4b (additional 
methods and results).
Respiratory tract symptoms and episodes
Following the method described by Johnston et al,2 participants were asked to fill 
in a diary, starting the day after vaccination, and daily score symptoms of upper 
and lower respiratory tract, use of medication, physician visits and other use of 
medical facilities. An episode of either URT or LRT symptoms was defined as 
two or more days with symptom scores above the median for that child preceded 
by at least one day at or below the median and followed by at least two days at 
or below the median (cf. Johnston et al.)2 [figure 1]. An asthma exacerbation 
was defined as an episode of LRT symptoms.
Further details are provided in chapter 4b (additional methods and results).
Virological and serological assessments
Throat swab material was analysed by culture, immunofluorescence and RT-PCR. 
A full description of the methods used is provided in chapter 4b (additional 
methods). 
We took blood samples (4 cc) before vaccination (sample 1), 14-21 days 
afterwards (sample 2) and at the end of the season, around the 1st of April 
(sample 3). The presence of influenza virus specific antibodies was performed by 
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a hemagglutination inhibition assay; details are given in chapter 4b (additional 
methods and results).
A four-fold increase in post-season serum antibody titre (comparing sample 2 
and 3) was considered an indication for an influenza virus infection.
Sample size
We wanted to be able to detect a 50% reduction in the number of asthma 
exacerbations caused by influenza with α=0.05 and 80% power. Assuming a 
30% influenza incidence in the placebo group and 50% of these infected children 
reacting with an exacerbation, we aimed at a total number of 600 children, i.e. 
300 children per season.
Chapter 4b (additional methods and results) provides additional information 
on sample size calculation, randomisation procedure, blinding, assessment of 
adverse effects and statistical analyses.
Results
Altogether 144 family practices (200 physicians) participated. They selected 
3220 children and informed these children and their parents by letter about the 
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objectives of our study. In total, 1365 children were willing to participate. After 
inclusion and informed consent 697 children were randomised (first season 
297, second season 400) [figure 2]. One participant, after having received 
the study intervention, was mistakenly vaccinated by her family doctor as well 
and excluded because of protocol violation. Of the remaining participants, 347 
were vaccinated with influenza vaccine and 349 with placebo. In each group 
3220 children selected from primary care 
files received letter and reply form
1475 did not reply
380 refused
740 met inclusion criteria 
and signed informed consent
347 assigned
vaccine
349 assigned 
placebo
697 randomised
1365 positive
5 diaries lost3 diaries lost
344 analysed 344 analysed
1 excluded due to protocol violation
43 withdrew informed consent
625 were excluded 
       196 did not meet inclusion criteria
         77 already vaccinated for present season
       352 did not give informed consent
figure 2. trial profile
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344 participants provided diary data for primary outcomes. The proportion of 
diary days for which no data were available was 4.7%. Because the number of 
missing diaries was very small, we decided not to impute data but to exclude 
these children from the analysis for these outcomes. 
Baseline characteristics
The groups were similar for baseline characteristics except for history of allergy 
[table 1]. Almost 90% of children had used maintenance medication for asthma 
during the previous 12 months; 55% of the children had been vaccinated against 
influenza before.
table 1. baseline characteristics of the study population (n=696)
 vaccine Placebo
Values are percentages unless otherwise stated n=347   n=349
age in years, mean (SD) 10.5 (3.2) 10.6 (3.3)
female sex 48.1 43.6
age of onset of asthma in years, mean (SD) 3.5 (3.8) 3.3 (3.4)
asthma complaints more than once a week previous 12 months 15.6 18.6
only maintenance medication in previous 12 months 29.1 24.4
relief and maintenance medication in previous 12 months 59.9 64.8
FEV1-% predicted, mean (SD) 89.5 (16.1) 88.9 (16.0)
ever treated by asthma specialist 40.7 46.6
still treated by asthma specialist  25.9 27.1
ever hospitalised for asthma 16.2 17.0
vaccinated previous season for influenza 51.4 53.0
ever vaccinated for influenza 53.6 56.7
if vaccinated before, number of seasons, mean (SD) 2.9 (1.9) 2.8 (1.8)
history of allergy 73.5 66.1
proven allergy for pollen, house dust mite, or pets 47.3 44.7
history of eczema 50.6 48.4
seasonal influence on asthma 74.4 77.0
family history of asthma 78.7 77.1
exposure to cigarette smoke at home 30.3 33.2
current smoker 2.6 2.6
pets at home 58.2 59.6
child born in the Netherlands 97.7 98.9
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Influenza activity
In our study, in the season 1999-2000 the first influenza positive swab was taken 
on 17 December 1999 and the last one on 20 January 2000. All were influenza 
A virus and the four cultures from these swabs all yielded H3N2. Dutch primary 
care sentinel stations detected influenza A H3N2 from week 45 (8 November) 
in 1999 until week 8 (21 February) in 2000.14
In the season 2000-2001 in our study the first influenza A virus was detected on 
21 November 2000 and the last on 23 March 2001. All cultures yielded H1N1. 
Three influenza B positive swabs were obtained between 7 and 13 March 2001. 
This season sentinel stations reported influenza A H1N1 from week 50 (11 
December) in 2000 until week 8 (19 February) in 2001. Influenza B was spotted 
in week 8 (19 February 2001-26 February 2001).15
table 2.  influenza viruses detected by either culture, 
immunofluorescence or pcr in pharyngeal swabs  
collected upon calls for airway symptoms
absolute numbers 1999-2000 2000-2001 total
 vaccine placebo vaccine placebo 
total number of calls 112 111 139 124 486
influenza A 2 (2) 6 (7) 20 (21) 13 (9) 41 (39)
influenza B 0 0 1 (1) 2 (2) 3 (3)
In parentheses: number of asthma exacerbations linked to positive swab results
Primary outcome
We received 486 calls (from 347 children) to report a symptom score of 4 points 
or more, 251 from the vaccine group and 235 from the placebo group. In 44 
of the throat swabs collected upon these calls, influenza virus was detected 
[table 2], of which 38 (21 in vaccine group, 17 in placebo group) could be 
linked to one or more asthma exacerbations, our primary outcome measure. 
This resulted in 42 influenza-related exacerbations. Of these, 24 were found in 
the group that received influenza vaccination and 18 in the placebo group, a 
difference of 33% (crude) or 31% after adjustment (95% CI ranging from 34% 
reduction to 161% increase) [table 3]. 
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The mean length of an influenza-related asthma exacerbation was 9.2 (vaccine 
group) and 11.2 (placebo group) and after adjustment for confounders, 3.1 
days longer in the placebo group (p=0.06). There were no differences in severity 
[table 3] (p=0.11).
Respiratory tract episodes 
From the diary data, 2311 asthma exacerbations and 2770 URT episodes were 
constructed [table 3]. The mean length of all asthma exacerbations (irrespective 
of causative agent) was 0.8 days longer in the placebo group (p=0.01). There was 
no difference in number and severity of exacerbations, nor in number, duration 
and severity of URT episodes. The proportion of days with respiratory symptoms 
did not differ between groups: 26 versus 27% for asthma symptoms and 33 
versus 29% for URT symptoms respectively for vaccine group and placebo 
group [table 3].
Subgroup analysis by vaccination history did not reveal any differences between 
children that had been vaccinated before and those that were vaccinated for the 
first time.
Medication, health care utilisation and absenteeism 
The use of various categories of medication (maintenance, relief, oral steroids, 
antibiotics, etc.) analysed both as number of doses, number of courses and 
proportion of days with medication, did not differ between the groups. Unscheduled 
visits to family doctor or specialist, and the number of absent days from school or 
work for participants and parents did not differ between the two groups. None 
of the children was admitted to hospital for airway problems.
One of the outcomes not reported in this paper, is quality of life during the 
asthma exacerbations. A paper describing the translation and validation of the 
questionnaire used to assess quality of life has been submitted. Another paper, 
studying various secondary outcomes in more detail, is in preparation.
Serological results
Blood samples were obtained on all three occasions from 651 children. A 
considerable number of children already had protective antibody levels (≥40) 
before vaccination, due to previous vaccinations and/or natural infections (Table in 
chapter 4b (additional methods and results)). Antibody levels and the proportion 
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with antibody levels of at least 40 at 14-21 days after vaccination all showed 
differences in favour of the vaccine group. Comparing second and third samples, 
(taken two to three weeks after vaccination and at the end of the season) in 
the placebo group 17.5% of participants had at least a fourfold rise for H1N1, 
4.0% for H3N2 and 0.9% for influenza B, compared to 7.0%, 1.2% and 1.8%, 
respectively, in the vaccine group.
Adverse reactions
During the first seven days after vaccination, injection site redness was reported 
significantly more often in the vaccine group than in the placebo group (31% vs. 
8%), as were stiff or painful arms (65% vs. 25%) and myalgia (20% vs. 11%). 
We found no differences for reported airways symptoms during the first week, 
nor for medication use, health care utilisation and absenteeism.
Discussion
This study shows that influenza vaccination was not more effective than placebo 
in reducing the number of asthma exacerbations caused by influenza infections 
in children. The duration of influenza-related asthma exacerbations was three 
days shorter in the vaccine group, but this was not statistically significant. 
There was no difference in severity. Regarding the other secondary endpoints, 
vaccinated children had shorter exacerbations (irrespective of their cause) and 
fewer seroconversions than the placebo group, but reported more side effects. 
There was no difference in proportion of days with asthma symptoms.
For both seasons, the vaccine strain matched well with epidemic virus strains.14, 15 
For children, the Dutch influenza bulletins reported a low number of influenza 
positive cases in 1999-200016 and a possible epidemic increase in 2000-2001,17 
both of which are in accordance with our findings. The second season was 
unusual because of the relatively extensive circulation of subtype H1N1 and the 
low activity of subtype H3N2.15
We found no difference in the number of influenza-related asthma exacerbations 
between both groups, although the vaccine group had a significantly higher 
protective level of IgG. Is there a possible explanation for this lack of effect? 
Studies in healthy subjects have shown that parenteral inactivated influenza 
vaccine does not induce as good an IgA response in the mucous membranes of 
the respiratory tract (being the first line of defence)18 as does priming by natural 
infection or intranasally administered influenza vaccine.19-23 Hence, we speculate 
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that parenteral vaccination may be relatively ineffective in preventing mucosal 
infection with influenza virus and subsequent asthma exacerbations.
After the 1986 study of Stenius-Aarniala24 this is the first randomised trial 
investigating parenteral influenza vaccination that takes influenza-related asthma 
exacerbations as an outcome.7 As the study of Stenius-Aarniala was unsuccessful 
due to extremely low influenza activity, we cannot compare our findings. Recent 
non-randomised studies in asthmatic children showed conflicting results.25-29
Was our study sample large enough? We were surprised by the low number 
of influenza-positive swabs, especially in the first season. Our choice to use 
pharyngeal swabs may have played a role, but compared to nasopharyngeal 
aspirates sensitivity is only about 20% lower.30 By recruiting more children than 
originally planned in the second season, we hoped to compensate for the low 
incidence in the first season. The final answer to the power question is given by 
our results, especially the 95% confidence interval for the primary endpoint.31 
The interval ranges from 34% reduction to 161% increase. This firmly excludes a 
50% reduction of influenza-related asthma exacerbations by vaccination, which 
we considered to be the threshold for clinical relevance.
Even a 35% reduction by vaccination is excluded by the confidence interval. 
Our finding of no difference is further corroborated by the lack of differences on 
almost all our other clinical outcome measures, as shown in table 3.
In previous studies, seroconversion throughout the influenza season was often 
the most important outcome measure to assess effectiveness of influenza vaccines. 
However, this outcome measure has serious shortcomings as a proxy measure 
for influenza infection.32 The most important problem is that seroconversion is 
more difficult or even impossible to attain in subjects with elevated titre levels 
at the start of the season.33 
A closer look at the difference in mean duration of all asthma exacerbations 
revealed that extremely long episodes (more than three standard deviations above 
mean) were found more often in the placebo group than in the vaccine group 
(n=12 vs. n=4). Most of these episodes began before influenza activity started 
in the Netherlands, which makes it likely that the difference in duration was a 
chance finding, not caused by the difference in treatment assignment. 
Regarding adverse reactions, we found differences between groups for local 
symptoms (red or stiff arm) and myalgia, as reported in previous studies.33, 34 There 
has been some debate about exacerbations as a direct result of vaccination.34, 35 In 
the present study, we found no differences in airway symptoms during the week 
after vaccination, making vaccination-induced airway symptoms unlikely.
We found relatively few influenza-related asthma exacerbations (9.1% of all calls, 
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1.8% of all asthma exacerbations). Given the proportion of children that showed 
a fourfold increase of antibodies during the season, a considerable number of 
influenza infections apparently did not give symptoms, or gave symptoms that 
were not severe enough to pass our predefined threshold.
Inevitably, our episode definition, although used before,2 has arbitrary elements. 
Other cut-off points for the number of days between two episodes would give 
different results. For our primary endpoint, 4 children had two episodes related 
to the same throat swab that could be counted as one episode by stretching 
this criterion from 2 to 3 days. Three of these children were in the vaccine 
group. However, the reduction in number of episodes in the vaccine group as a 
consequence of changing this criterion (still negative, and the confidence interval 
still excluding a 50% reduction) would be balanced by an increase in length of 
the episodes.
In conclusion, our randomised placebo-controlled study showed no relevant 
effect of influenza vaccination on the number and severity of influenza-related 
asthma exacerbations in asthmatic children. Vaccinated children tended to have 
shorter exacerbations throughout the season but reported more (mild) adverse 
effects after vaccination than children receiving placebo.
Both the limited effectiveness of influenza vaccination found in this study and 
the low incidence of influenza, observed in the first season, warrant additional 
studies to justify routine influenza vaccination of asthmatic children in general 
practice.
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4b.  Influenza vaccination in children with 
asthma: randomised double-blind 
placebo-controlled trial, additional 
methods and results
Inclusion
Possible participants were selected from computerised patient files by means of 
a preinstalled influenza prevention module, searching for asthma diagnoses and 
drug prescriptions specific for asthma.1 In the months August to October preceding 
the respective influenza seasons, eligible patients were visited and included if 
they had used maintenance therapy for asthma or more than 52 doses of relief 
medication during the previous 12 months. 
Exclusion criteria were diabetes, thyroid diseases, cystic fibrosis, kidney diseases, 
Down’s syndrome, congenital heart diseases and other chronic diseases for which 
influenza vaccination is advised, with the exception of asthma. Insufficient 
understanding of Dutch language resulted in exclusion for reasons of compliance 
and allergy to chicken protein did, because the antigens for influenza vaccines 
are produced in embryonated chicken eggs.
Research nurses were instructed and trained to perform inclusion visits, explain 
the objectives of our study and the use of the diaries, take throat swabs, use 
spirometers, give intramuscular injections and draw blood from children. 
At the inclusion visit they measured height and weight and performed spirometry. 
Lidocaine-prilocaine plasters were provided to reduce pain of drawing blood.
Vaccine and placebo
The vaccine composition for 1999-2000 was a combination of A/Sydney/5/97 H3N2-like, 
A/Beijing/262/95 H1N1-like and B/Beijing/184/93-like strains and for 2000-2001 A/
Moscow/10/99 H3N2-like, A/New Caledonia/20/99 H1N1-like and B/Beijing/184/93-
like strains as advised by the World Health Organisation. The placebo consisted of a 
buffered phosphate solution with the same pH value and was similar in appearance to 
the inactivated influenza vaccine. The manufacturer (Solvay Pharmaceutical Products, 
Weesp, the Netherlands) stored the vaccines after production at 2 to 8 °C. Vaccines 
were transported to and stored under optimal conditions at the central pharmacy of 
the University Hospital Rotterdam until shortly before vaccination.
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Outcomes
In addition to the outcomes mentioned in chapter 4a, we also studied proportion 
of days with symptoms of upper respiratory tract and/or lower respiratory tract 
(LRT), use of medication, unscheduled consultations of a specialist or family 
physician, admittance to hospital for airway problems, a rise in antibody-titre 
against influenza, and the number of influenza infections indicated by serology.
Respiratory tract symptoms and episodes
URT symptoms included sneezing, runny or stuffy nose, burning or watery eyes, 
sore throat, hoarseness, fever or shivering, headache, myalgia. LRT symptoms 
(asthma symptoms) included cough and wheeze during day and night, difficult 
breathing or shortness of breath. Respiratory tract symptoms were scored from 
1 (mild) to 3 (severe) and summated; not fit to go to school or work because of 
symptoms was scored as 2. Participants were instructed to phone the investigators 
when scores for upper or lower airway symptoms totalled 4 or more on a given 
day. As soon as possible, but within 48 hours after the call, a research nurse 
visited these children and took a pharyngeal swab. Nurses were instructed to rub 
the swab two times along the palatoglossal arch including the uvula.
All diary data were coded and entered into a database. For every child we 
calculated medians for URT and LRT symptoms over the period starting one 
week after vaccination and ending when diaries were returned (around the 1st 
of April). Symptoms scored in the first week were excluded because these were 
considered to be side effects of the vaccination.
A call reporting a symptom score of 4 or more was considered to coincide with an 
episode of URT symptoms if it occurred during the episode of URT symptoms. A 
call was considered to coincide with an asthma exacerbation if it occurred during 
or up to seven days before the asthma exacerbation. Severity was defined as the 
highest day score during the episode. When influenza virus was detected in the 
pharyngeal swab by any of the detection methods (see below) we assumed that 
the episode coinciding with the call was caused by this pathogen.
Virological assessments
Throat swabs were placed in 1 ml modified Eagles minimal essential medium 
supplemented with 500 U/ml penicillin, 500 g/ml streptomycin (all BioWhittaker) 
and 5 g/ml amphotericin B (Bristol Meyers Squibb). The swabs were transported 
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in a cool box and delivered at the laboratory within 36 hours. 0.2 ml of swab 
aspirate was transferred to shell vial cultures of human pharynx carcinoma cells, 
tertiary monkey kidney cells and human embryonic lung cells in 24 well plates. 
The plates were centrifuged at 3500 x g for 15 minutes, washed and subsequently 
cultured in culture medium at 37 °C and 5% CO2. The cultures were checked for 
cytopathologic effects daily. After 24-48 hours of culture, the coverslips of cells 
were removed from the shell vials, washed three times in phosphate buffered saline 
and fixed in acetone for 15 min at room temperature. Subsequently they were 
analyzed by immunofluorescence for respiratory viruses using specific reagents 
(Dako, Glostrup, Denmark). 
For reverse transcriptase polymerase chain reaction (RT-PCR), RNA was 
extracted from clinical samples using the high pure RNA isolation kit (Roche 
Molecular Biochemicals) and used as template. RT-PCR and subsequent dot-
blot hybridizations were performed as described previously for the detection of 
influenza A viruses.2 For influenza B, the following primers and probes were used: 
Primer forward (5’-ATG GCC ATC GGA TCC TCA AC) and primer reverse 
(5’-TGT CAG CTA TTA TGG AGC TG) for PCR amplification, hybridisation 
probe (5’-CAA GAG CAC CGA TTA TCA CCA GAA GAG GGA).
Serology
We took blood samples (4 cc) before vaccination (sample 1), 14-21 days afterwards 
(sample 2) and at the end of the season, around the 1st of April (sample 3). 
Samples were kept at room temperature and delivered at the laboratory within 
72 hours. 
For the detection of influenza virus specific serum antibodies a hemagglutination 
inhibition assay (HIA) was used, which was performed essentially as described 
previously,3, 4 using turkey erythrocytes for agglutination, a filtrate of cholera 
vimbriae as source of receptor destroying enzyme and four hemagglutinating units 
of the respective vaccine strains (X-127 (reassortant of A/Beijing/262/95(H1N1)), 
IVR-108 (reassortant of A/Sydney/005/97 (H3N2) and B/Yamanashi/166/98 for 
the 1999-2000 season and strains IVR-116 (reassortant of A//New Caledonia/
020/99(H1N1)), ResVir-17 (reassortant of A/Panama/2007/99 (H3N2)) and 
B/Yamanashi/166/98 for the 2000-2001 season), which were propagated in 
embryonated chicken eggs. Geometric mean titres (GMT) were calculated, as 
recommended for antibody titre data. A post-vaccination titre of at least 40 was 
considered to be a protective antibody level.5
A four-fold increase in post-season serum antibody titre (comparing sample 2 and 
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3) was considered an indication for an influenza virus infection [table].
table. serological results
 vaccine placebo p-value
Number of samples   
Sample 1 before vaccination 341 346 
Sample 2 two weeks after vaccination  342 343 
Sample 3 end of the season 329 328 
H1N1
Sample 1 antibody titre (geometric mean) 23.2 22.8 a
Sample 2 antibody titre (geometric mean) 200.7 23.0 <0.001
Sample 3 antibody titre (geometric mean) 188.0 38.0 <0.001
Sample 1, titre >40 38.7% 38.4% a
comparing samples 1 and 2, fourfold increase 59.9% 0.9% <0.001
sample 2, titre >40 85.6% 38.9% <0.001
comparing samples 2 and 3, fourfold increase 7.0% 17.5% <0.001
H3N2
sample 1 antibody titre (geometric mean) 87.2 78.9 a
sample 2 antibody titre (geometric mean) 227.1 79.4 <0.001
sample 3 antibody titre (geometric mean) 186.3 88.3 <0.001
sample 1, titre >40 78.3% 79.2% a
comparing samples 1 and 2, fourfold increase 27.1% 1.2% <0.001
sample 2, titre >40 98.5% 79.2% <0.001
comparing samples 2 and 3, fourfold increase 1.2% 4.0% 0.03
B
sample 1 antibody titre (geometric mean) 159.7 155.7 a
sample 2 antibody titre (geometric mean) 358.4 157.6 <0.001
sample 3 antibody titre (geometric mean) 338.4 156.6 <0.001
sample 1, titre >40 88.3% 87.9% a
comparing samples 1 and 2, fourfold increase 26.5% 0% <0.001
sample 2, titre >40 95.3% 87.7% <0.001
comparing samples 2 and 3, fourfold increase 1.8% 0.9% 0.26
a: differences at baseline not tested as these are the result of randomisation
Adverse effects
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Symptoms scored in the diaries during the first seven days after vaccination were 
considered to be adverse effects of the vaccination. Additionally, we asked during 
these seven days for red or painful arm, nausea, vomiting or diarrhoea, fatigue 
or sweating, other symptoms, contact with a physician, use of medication for 
these symptoms and absence from school or work for participants as well as 
for their parents.
A separate paper studying adverse effects in more detail has been submitted.
Spirometry
Forced expiratory volume in one second (FEV1) was performed at inclusion. We 
used a hand-held spirometer (Micro DL, Micro Medical Systems, Rochester, UK). 
Each time, the best result of three attempts was taken. Values were expressed as 
percentage of predicted values according to age, sex and height.6
Sample size
Sample size calculations were based on crude proportions, and did not take 
account of multivariate adjusting. We wanted to be able to detect a 50% reduction 
in the number of asthma exacerbations caused by influenza virus with α=0.05 
and β=0.2 (two-sided test). Reported infection rates, mainly based on serological 
data, have usually been in the range of 20-40% and were higher for children than 
for adults.7-9 Foy found that 40-54% of adolescents with serological evidence of 
infection reported clinical illness.10
Therefore, we assumed that 50% of infected children would react with an 
exacerbation. 
To allow for variation in both incidence and effectiveness, we chose to aim at a 
total number of 600 children for whom complete data would be available, i.e. 
300 children per season. This would allow us to show 50% reduction when 15% 
of the children in the placebo group would show influenza-related exacerbations 
(30% influenza incidence and 50% of these children with exacerbation).
In the first season, we obtained data from 297 children. However, only eight 
positive throat swabs were found, which is much less than we expected. Because 
of this we seriously considered to stop the study. Data from the National Influenza 
Centre made clear, however, that the season had been atypical because of the low 
influenza activity in children.
After careful consideration of various scenarios we decided to continue and make 
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an effort to include more participants during the second season. We aimed at 
recruiting as many children as possible with the available personnel, and ended 
up with exactly 400 children, giving a total of 697 children.
Randomisation
Randomisation took place by the manufacturer when packing vaccine and placebo, 
from a computer-generated list. We randomised patients in blocks and stratified for 
vaccination in the past, because this may be a confounder for vaccine efficacy.11, 12 
Randomisation codes were stored by the manufacturer and in sealed envelopes 
at the central pharmacy of the University Hospital Rotterdam. The pharmacist 
was not involved in outcome assessment or data analysis.
Blinding
Patients and parents, general practitioners, research nurses and investigators 
were all blinded. Randomisation codes were broken after completion of the 
analyses.
Statistical methods
We analysed the results by intention to treat. No interim analyses were performed. 
Differences in proportions were tested by χ2-tests (Fisher’s exact test). The ratio 
(vaccine/placebo) of the number of episodes and of the number of medication 
courses (oral prednisone and antibiotics) was estimated; the null hypothesis of 
no difference was tested by means of Poisson regression (robust SE). Differences 
between groups in occurrence of episodes (yes/no) were tested by means of 
logistic regression analysis. Differences in length and severity of episodes between 
groups were tested by means of linear regression for repeated measurements, 
taking children with episodes as units of analysis. Differences between groups 
in proportion of days with symptoms, medication, physician visits, number 
of absent days and number of doses medication was tested by means of linear 
regression analysis. The difference between groups for occurrence of symptoms 
during the first seven days after vaccination was tested by logistic regression for 
repeated measurements. Baseline characteristics that had at least a weak relation 
(p <0.25) with the outcome variables were considered to be potential confounders. 
The adjustments for these potential confounders were made through relevant 
multiple regression models. Serological data were analysed univariately by means 
73
of χ2-tests (in case of proportions) and analysis of variance (titre levels). All tests 
were two-sided with a significance level of 0.05.
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5.  Responsiveness, longitudinal and 
cross-sectional construct validity of 
the Pediatric Asthma Quality of Life 
Questionnaire (PAQLQ) in Dutch 
children with asthma
Abstract
Health-related quality of life is an important measure in evaluations of the 
management of childhood asthma. In this study, we assessed psychometric 
properties, responsiveness, and longitudinal and cross-sectional construct validity 
of the Dutch version of the 23-item Pediatric Asthma Quality of Life Questionnaire 
(PAQLQ).
The study group consisted of 238 6-18 year-olds with asthma, with complete 
respiratory symptom diaries and at least two PAQLQ measurements (one relating 
to a week with relatively few, and one to a week with relatively many symptoms) 
during one winter season. The PAQLQ scores for a week with few symptoms 
(the symptom diary scores remained below a predefined level everyday) were 
compared with the PAQLQ scores for a week with many symptoms (on day 1, 
symptom diary scores were above the predefined level). Additionally, the PAQLQ-
scores for two subsequent periods with many symptoms were compared in 101 
children.
Only the domain Emotions showed a ceiling effect (>25% had the maximum 
score). All Cronbach’s α’s of the PAQLQ total score and domains were >0.70, 
except for Activities. Mean PAQLQ-score changes between periods with few 
versus many symptoms (n=238) were significantly different (p <0.01) from changes 
between two consecutive periods with many symptoms (n=101), which indicates 
responsiveness. (Changes in) lower respiratory tract symptoms, indicative of 
asthma severity, correlated better with (changes in) PAQLQ scores than (changes 
in) upper respiratory tract symptoms, which supports the longitudinal and cross-
sectional construct validity. 
The assessed properties of the PAQLQ linguistic validation into Dutch were 
similar to those originally established for the PAQLQ in Canada. This study 
78
showed that the Dutch PAQLQ has adequate psychometric properties, excellent 
responsiveness, and that the longitudinal and cross-sectional construct validity 
is supported. 
Introduction
Health-related quality of life is an important measure, complementary to clinical 
and physiological parameters, in evaluations of the management of childhood 
asthma,1-9 a very prevalent chronic condition.10 The Pediatric Asthma Quality 
of Life Questionnaire (PAQLQ), developed by Juniper et al., is a widely used 
disease-specific health-related quality of life measure for children and adolescents 
aged 7-17 years.3, 11 It has 3 domains: symptoms (10 items), activity limitations 
(5 items), and emotional function (8 items).3 All items have 7 response options. 
Usually, the mean item score (or change in mean score) is reported per domain 
and for the whole instrument. Scores range from 1-7, where higher scores indicate 
better quality of life.3
The PAQLQ was first applied in Canada and has since been used in several 
other countries.3, 12-15 A PAQLQ linguistic validation into Dutch was performed 
following a rigorous process including two independent forward and backward 
translations and a cognitive debriefing on 10 children with asthma.16-18
This study aims to evaluate the Dutch PAQLQ by assessing:
(a)  psychometric properties (score distributions to assess floor and ceiling 
effects; internal consistency of the domains; test-retest reliability);
(b)  evaluative properties (ability to detect changes between periods with 
differences in reported respiratory symptoms as indicator of responsiveness; 
correlation coefficients between changes in reported respiratory symptoms 
plus other indices of severity and changes in PAQLQ scores as indicator of 
longitudinal construct validity);19 
(c)  discriminative properties (correlation coefficients between the level of 
reported respiratory symptoms plus other indices of severity at a point in 
time and PAQLQ scores at that time as indicator of cross-sectional construct 
validity).19
The PAQLQ cross-cultural adaptation into Dutch will be regarded as successful 
when the PAQLQ measurement properties are similar to those that were originally 
found in Canada and other countries.3, 12-15, 20
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Methods
Study population and data collection
The study group consisted of 238 6-18 year-olds with asthma, with complete 
respiratory symptom diaries and at least two PAQLQ measurements (one relating 
to a week with relatively few, and one to a week with relatively many symptoms) 
during one winter season (1999-2000 or 2000-2001); the study population 
was drawn from 696 children with asthma selected from 144 general practices 
who were included in a randomised double-blind placebo-controlled trial of 
influenza vaccination.21 During the year previous to inclusion, all had used asthma 
maintenance therapy or more than 52 doses of relief medication. 
Socio-demographic variables, age at asthma onset, history of allergy, medication 
and FEV1-% predicted
22 were assessed at inclusion; the results are shown in 
table 1. Upper- and lower respiratory tract (URT and LRT) symptoms and use 
of β-agonists were recorded in the respiratory symptom diaries. URT symptoms 
included sneezing, runny/stuffy nose, burning/watery eyes, sore throat, hoarseness, 
fever/shivering, headache, and myalgia. LRT (asthma) symptoms included cough 
and wheeze during day and night, difficult breathing or shortness of breath. 
Symptoms were scored from 1 (mild) to 3 (severe) and summated; not fit to go 
to school/work because of symptoms was scored as 2.21
If URT or LRT scores totalled 4 or more on a certain day, participants were 
instructed to phone the research nurse, who –within 48 hours– assessed FEV1-% 
predicted22 and –after 7 days– assessed the PAQLQ for the preceding week 
(referred to as a period with many symptoms). The participants were also visited 
for ‘baseline’ measurements of FEV1-% predicted
22 and PAQLQ evaluation over 
a period with few symptoms (7 consecutive days during which symptom diary 
scores were below 4 URT/LRT-points on all days).
Pairs of PAQLQ scores, made up of a period with few and a period with many 
respiratory symptoms, were established and assessed for the 238 participating 
children, with random selection of the period with many symptoms in the event 
a child had reported experiencing two or more periods with many symptoms. 
Additionally, a subgroup of 101 children was distinguished from whom two (or 
more) consecutive PAQLQ measurements of periods with many symptoms had 
been obtained; two periods/measurements were randomly selected if a child 
had reported three or more periods with many symptoms. We evaluated pairs 
of PAQLQ-scores relating to two consecutive periods with many symptoms for 
these 101 children.
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table 1. characteristics of the study group (n=238)
  
Variable n % of participants mean (SD)
Age group (years)
 6-10 137 57.6
 11-14 68 28.6
 15-18 33 13.9
 Mean (SD)    10.8  (3.2)
Gender
 Girls 121 50.8
Mean age (years) at asthma onset (SD)    3.3  (3.5)
FEV1-% predicted (at inclusion)
 <80% 51 21.8
 ≥80% 183 78.2
 Mean (SD)    88.7% (13.7)
FEV1-% predicted (at a day with symptoms-diary-score below the predefined level)
 <80% 40 17.5
 ≥80% 189 82.5
 Mean (SD)    92.9%   (14.2) 
FEV1-% predicted (at a day with symptoms-diary-score above the predefined level)
 <80% 75 34.2
 ≥80% 144 65.8
 Mean (SD)    84.5% (19.2)
Child has history of allergy 
 Yes 127 53.3
Child has used inhalation steroids during 12 months prior to inclusion
 Yes 221 92.9
Child born in the Netherlands
 Yes 236 99.2
Parents sharing household
 Yes 224 94.1
 
Educational level of mother
 Elementary school 7 3.0
 Secondary education 188 80.7
 Higher education/university 38 16.3
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Analysis
We assessed PAQLQ score distributions to evaluate floor and ceiling effects, arbitrarily 
defined as >25% of the respondents having the maximum respectively minimum 
score,23 and Cronbach’s α’s as measure of internal consistency of the domains.24 Test-
retest reliability was evaluated preliminarily by Intraclass Correlation Coefficients 
(ICCs)25 between scores at two periods with many symptoms (n=101; see Discussion). 
Responsiveness was evaluated by assessing the mean change in PAQLQ scores between 
a period with few and a period with many symptoms (n=238). This was contrasted 
with the mean change between two periods with many symptoms (n=101). Mean 
change was tested by two-sided Wilcoxon’s signed ranks tests. Cohen’s effect size 
was used to indicate the relative magnitude of change: d = [Mean(a) – Mean(b)]/SD 
concerning a period with many symptoms, respectively the 2nd measurement*.26 The 
mean change between few versus many symptoms was compared with the change 
between two periods with many symptoms; this was tested by 2-sided Mann-Whitney 
U tests. Longitudinal construct validity was evaluated by assessing Spearman rank 
order correlation coefficients between the change in URT/LRT-symptoms/β-agonist use/ 
FEV1-% predicted and PAQLQ changes (n=238). Cross-sectional construct validity was 
evaluated by assessing Spearman rank order correlation coefficients between URT/LRT 
diary-scores/β-agonist use/FEV1-% predicted and PAQLQ scores. This was performed 
for measurements relating to both periods with few symptoms (n=238) as well as 
periods with many symptoms (n=238); so, with regard to 476 measurements. 
All analyses were done in SPSS, Version 10.0. Parents/children gave informed consent; 
the Medical Ethical Committee of Erasmus MC-University Medical Center Rotterdam 
approved the study.
Results 
Psychometric properties 
There was no evidence of any ceiling or floor effect for the PAQLQ total score 
and the domain scores, except for the Emotional function domain [table 2]. 
Cronbach’s α’s of the PAQLQ overall score and the domain scores were all 
above 0.70 indicating excellent internal consistency, except for Activities (α 
<0.70) [table 2]. Test-retest ICCs between two periods with many symptoms, 
were generally low (defined as <0.50) or moderate (0.50-0.75), and one time 
excellent (>0.75)27 [table 3a].
*  Following Cohen’s guidelines, 0.2≤ d <0.5 indicates a small effect, 0.5≤ d <0.8 a moderate effect 
and d ≥0.8 a large effect. 26
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Responsiveness
The mean change in PAQLQ scores between a period with few and a period with 
many symptoms was fairly stable across three age groups (total score: 0.79-1.11 
points difference) [table 3]. The corresponding effect sizes ranged from 0.80-
1.19 (indicating large effects), except for Emotions (0.40-0.50). PAQLQ-score 
changes between a period with few and one with many symptoms (n=238) were 
significantly larger than PAQLQ-score changes between two periods with many 
symptoms (n=101) (p <0.01), indicating excellent responsiveness.
Longitudinal and cross-sectional construct validity
All correlation coefficients assessing construct validity in table 4 were in the 
expected direction; however, all were either small (defined as <0.50) or moderate 
(0.50-0.75).26 (Changes in) lower respiratory tract symptoms, indicative of asthma 
severity, correlated better with (changes in) PAQLQ scores than did (changes in) 
upper respiratory tract symptoms, which supports the longitudinal and cross-
sectional construct validity. The symptoms PAQLQ-domain showed the highest 
correlation coefficients with all indicators, except for FEV1-% predicted.
Discussion
Evaluation of measurement instruments, including cross-cultural validation, is 
a continuous endeavor requiring studies in diverse clinical populations across 
countries.20 This study, performed in a relatively large sample of children with 
asthma, supports the cross-cultural validity of the Dutch version of the PAQLQ. 
It showed psychometric properties and indicators of responsiveness and construct 
validity of the Dutch PAQLQ that were similar to those originally established for 
the PAQLQ in Canada3 and later in other countries.12-15 Limitations of our study 
include the sample and assessment of test-retest reliability and responsiveness. 
The study population that was sampled from general practices consisted mainly 
of moderate cases of asthma; we do not know the results in –sometimes more 
heterogeneous– hospital-based populations. The evaluation of PAQLQ test-retest 
reliability was only preliminary, as some of the children may not have been in 
a stable clinical state during one or both of the two different periods, each with 
many symptoms, that were evaluated, this may have contributed to the relatively 
low test-retest ICCs.3 In order to evaluate the responsiveness of the PAQLQ, we 
contrasted PAQLQ mean score differences within pairs of weeks (per child, for 
86
all children in the study group) where 1 week of the pair had many and the other 
week had few reported diary-symptoms with, in a subgroup of the same children, 
the PAQLQ mean score differences within other pairs of weeks (per child in the 
subgroup) where both weeks within a pair had many reported diary symptoms. 
In future studies, for the evaluation of responsiveness, we recommend adding 
other measures of disease stability than the number of reported diary-symptoms. 
Overall the measurement properties of the Dutch version of the PAQLQ were 
adequate and there were only two results that gave rise to some concern. (1) 
The Emotions domain showed ceiling effects, which may, to some degree, limit 
its use in detecting changes and describing health. (2) The internal consistency 
of the Activities domain was sub-optimal in our sample (Cronbach’s α <0.70), 
which may have contributed to the relatively low test-retest ICC in the youngest 
subgroup; we propose to reevaluate the internal consistency of the Dutch version 
of the Activities domain in future studies.
This study showed that the Dutch PAQLQ has satisfying psychometric properties, 
excellent responsiveness, and that longitudinal and cross-sectional construct 
validity is supported. Issues that require attention are the consequences of the 
ceiling effects of the domain Emotions, the internal consistency of the domain 
Activities and the test-retest reliability of the Dutch PAQLQ.
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6.  Influenza vaccination in asthmatic 
children: effects on quality of life  
and symptoms
Abstract
This study aimed to detect the effect of influenza vaccination on quality of 
life, symptomatology and spirometry in asthmatic children. We performed a 
randomised double-blind placebo-controlled trial in 696 (296 in 1999-2000 and 
400 in 2000-2001) asthmatic children 6-18 years of age which were vaccinated 
with either vaccine or placebo. Children participated for only one influenza 
season. They recorded symptoms in a diary and reported when symptom scores 
reached a predefined severity level. If so research nurses visited them twice, first 
to take a pharyngeal swab and spirometry, and a week later to assess quality of 
life over the past illness week.
Compared to placebo, vaccination improved health-related quality of life in the 
weeks of illness related to influenza-positive swabs. However, no effect was found 
for respiratory symptoms recorded in the diaries during those weeks. Similarly, no 
differences were found for quality of life in all weeks of illness or for respiratory 
symptoms throughout the seasons.
Our conclusion is that influenza vaccination has a moderate beneficial effect on 
quality of life in influenza-positive weeks of illness in children with asthma. 
Introduction
Influenza vaccination in children with asthma is recommended in most of Europe 
and North America.1 Surprisingly there are no randomised controlled trials 
confirming that vaccination is beneficial in this group.2 We recently reported the 
results of influenza vaccination in asthmatic children and did not find an effect 
on the number of influenza-related asthma exacerbations, or on their duration 
or severity; however, we did find that vaccination shortens the duration of all 
asthma exacerbations by 0.8 day, irrespective of their cause.3
Asthma exacerbations inform us about the status of the pulmonary system but 
will not capture the functional impairments (physical, emotional, and social) that 
are important in children’s everyday lives.4 Apart from preventing exacerbations, 
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improvement of the well-being of asthmatic children should also be an important 
goal of the vaccine treatment. Influenza season has significant adverse effect on 
the quality of life of school age children and their families.5 Influenza vaccine, 
by inducing a protection against influenza infection and subsequent illness, will 
reduce systemic and respiratory illness. It also will diminish related morbidity 
such as missed schooldays, physician visits and the use of medication. This 
obviously will affect certain domains of quality of life, e.g. symptoms, activity 
limitations and emotions. 
This study reports whether influenza vaccination has an effect on children’s 
asthma-related quality of life during weeks of illness, on respiratory symptoms 
and on spirometric parameters in the corresponding periods, and on all symptoms 
throughout the seasons. To verify that the results are not confounded by 
differences in viral infections between groups, we also report on the viruses that 
were detected.
Methods
We conducted a randomised double-blind placebo-controlled parallel trial in 
children with asthma recruited through general practitioners (GPs) in the city of 
Rotterdam and its surroundings during two influenza seasons, 1999-2000 and 
2000-2001. Here we briefly summarize the design which has been described in 
detail elsewhere.3
Participants
Children aged 6-18 years were included if they had used maintenance therapy 
for asthma or more than 52 doses of relief medication during the previous 12 
months. Children could participate for only one season. Exclusion criteria were 
other chronic diseases, allergy to chicken protein and insufficient understanding of 
the Dutch language. The Medical Ethical Committee of Erasmus MC-University 
Medical Center Rotterdam approved the study.
Intervention
In both seasons, research nurses parenterally vaccinated all participants between 
25 October and 24 November with either inactivated influenza vaccine or placebo. 
The vaccine composition for 1999-2000 was a combination of A/Sydney/5/97 
H3N2-like, A/Beijing/262/95 H1N1-like and B/Beijing/184/93-like strains and 
for 2000-2001 A/Moscow/10/99 H3N2-like, A/New Caledonia/20/99 H1N1-like 
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and B/Beijing/184/93-like strains as advised by the World Health Organisation. 
The placebo consisted of a buffered phosphate solution with the same pH value 
and was similar in appearance to the inactivated influenza vaccine.
Objectives
The study aimed to answer whether influenza vaccination in children with 
asthma has an effect on asthma-related quality of life, respiratory symptoms 
and spirometric parameters during weeks of illness and on their symptomatology 
throughout the influenza season.
Quality of life
Health related quality of life was assessed by means of the Dutch version of the 
23-item Pediatric Asthma Quality of Life Questionnaire (PAQLQ), which we 
recently validated. 6, 7 The PAQLQ consists of the domains symptoms (10 items), 
activities (5 items) and emotions (8 items). The instrument measures well-being 
over a previous period of 7 days, a period which covers the usual period of 
symptoms and signs typically due to influenza. The score for every item ranges 
from 1-7, with higher scores indicating a better quality of life.
When children reached the threshold of the severity level for symptoms a PAQLQ 
was administered one week later. In case of multiple weeks of illness we calculated 
the mean PAQLQ values. For all children, a baseline PAQLQ was administered 
when upper respiratory tract infection (URT) and lower respiratory tract infection 
(LRT) symptom scores had been beneath the threshold of 4 points for a period of at 
least seven days. We considered a change between the total scores or domain scores 
of baseline versus illness of at least 0.5 points as a minimal important difference 
(MID). The clinical relevance of this difference was assessed previously.6
Symptom scores and weeks of illness
Participants (or their parents) were asked to fill in a diary, starting the day after 
vaccination, and daily score symptoms of URT and LRT. URT symptoms included 
sneezing, runny or stuffy nose, burning or watery eyes, sore throat, hoarseness, 
fever or shivering, headache and myalgia. LRT symptoms (asthma symptoms) 
included cough and wheeze during day and night and difficult breathing or 
shortness of breath. If present, respiratory tract symptoms were scored from 
one (mild) to three (severe) and summed; not fit to go to school or work because 
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of symptoms was scored as two. We instructed participants to telephone the 
investigators when the summated scores for either URT or LRT symptoms totalled 
four or more on a given day. As soon as possible, but within 48 hours after the 
call, a research nurse visited the child, took a throat swab for the detection of 
viruses and performed spirometry. This procedure was adopted from Johnston 
et al.8 One week later, nurses administered a PAQLQ. We defined these weeks, 
starting with a predefined severity level for respiratory symptoms as “weeks of 
illness”.
Spirometry
A handheld spirometer (Micro DL Micro Medical Systems UK) was used, 
standardised in accordance with the recommendations of the American Thoracic 
Society, and measured forced expiratory volume in one second (FEV1), forced 
vital capacity (FVC), and maximum expiratory flow at 25% of FVC (MEF25) 
and maximum expiratory flow at 50% of FVC (MEF50). On each occasion 
spirometry was performed three times and the best result was taken. We obtained 
spirometric data at inclusion, at the same moment as the baseline PAQLQ, and 
at the start of a week of illness. When children had multiple weeks of illness 
the mean spirometric values were calculated. Values for FEV1 and FVC were 
expressed as percentage of predicted values according to age, gender and height 
following the procedure proposed by Quanjer et al.9 and for MEF25 and MEF50 
as proposed by Rosenthal et al.10
Virological assessments
Throat swabs were cultured and searched for the presence of influenza virus 
A and B as described earlier3 and the same method was applied for detecting 
parainfluenza 1, 2 and 3, adenovirus and respiratory syncytial virus. Subsequently 
they were analyzed by immunofluorescence for respiratory viruses using specific 
reagents (Dako, Glostrup, Denmark). Throat swabs were also tested by polymerase 
chain reaction (PCR) for influenza A and B11 and rhinoviruses.12
Randomisation and blinding
Randomisation, packing and labelling took place by the manufacturer of the 
vaccine. All those involved, i.e. patients and parents, general practitioners and 
investigators, were blinded. 
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Statistical methods
We analysed the data by intention to treat. Differences between groups were 
analysed by Fisher’s exact test in case of proportions and by analysis of variance 
for continuous data. 
Results
A total of 200 GPs in 144 practices participated. GPs selected 3220 children and 
informed them and their parents by letter about the objectives of our study. In 
total, 1365 children were willing to participate. After inclusion and informed 
consent, 696 children participated. Of these, 347 were vaccinated with influenza 
vaccine and 349 with placebo. In each group 344 participants provided diary 
data. We have already described this trial profile in detail.3 In the two seasons the 
study was conducted (1999-2000 and 2000-2001), the influenza vaccine strains 
matched well with epidemic virus strains.13, 14
Characteristics at inclusion and at baseline
The groups were similar for characteristics at inclusion and baseline except for 
history of allergy [table 1]. Of all children, 55% had been vaccinated against 
influenza before.
Outcomes
Weeks of illness
We received 486 telephone calls reporting a score of 4 points or more concerning 
347 children of which 178 children were in the vaccine group and 169 children 
were in the placebo group. In the vaccine group 117 children reported once, 
40 twice, nine three, two four and one five time(s). In the placebo group 123 
children reported once, 43 twice, nine three, two four and one five time(s). For 
342 of these 347 children one or more outcomes during weeks of illness were 
available, 176 in the vaccine group and 166 in the placebo group. There were 
43 weeks of illness in which influenza virus was detected (one double infection 
with influenza A and B), 22 in the vaccine group and 21 in the placebo group. 
Of those influenza-positive weeks, data on quality of life were available in 40 
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cases and on symptoms and spirometry in 42 cases.
table 1. baseline characteristics of the study population (n=696)
 vaccine placebo
At inclusion visits n=347 n=349
mean (SD) unless otherwise stated 
age in years, mean (SD) 10.5 (3.2) 10.6 (3.3)
female gender 48.1% 43.6%
age of onset of asthma in years, mean (SD) 3.5 (3.8) 3.3 (3.4)
ever vaccinated for influenza 53.6% 56.7%
history of allergy 73.5% 66.1%
child born in the Netherlands 97.7% 98.9%
FEV1-% predicted, mean (SD)  89.5 (16.1) 88.9 (16.0)
At baseline visits
quality of life *(values are mean symptom scores) n=331 n=331
total score 6.16 6.16
activities  5.60 5.60
emotions  6.63 6.63
symptoms  6.05 6.05
spirometry (mean (SD)) n=332 n=337
mean FEV1  2.13(.76) 2.13(.80)
% predicted 93(14) 92(13)
mean FVC 2.43(.88) 2.43(.96)
% predicted  92(14) 90(14)
mean MEF50 2.68(1.10) 2.66(1.0)
% predicted 90(25) 90(24)
mean MEF25 1.42(.71) 1.42(.67)
% predicted 94(36) 96(36)
* Scores range from 1-7, with higher scores indicating a better quality of life.
Quality of life
A baseline PAQLQ was obtained from 662 children, 331 in the placebo group 
and 331 in the vaccine group. For all children baseline scores both for the total 
score and the domain scores did not differ between the groups.
In 333 children a PAQLQ for a baseline week and a PAQLQ during one or 
more illness weeks was recorded. In children who reported weeks of illness no 
differences in baseline were found between the vaccine group and the placebo 
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group.
Differences between baseline PAQLQ scores and scores during influenza positive 
weeks of illness favoured the vaccine group, as did differences in the symptoms 
and activities domains [table 2], whilst there were no differences between baseline 
scores and scores in weeks of illness irrespective of their cause. The proportion of 
children reaching the minimal important difference for the symptoms domain in 
influenza-positive weeks as well as in all weeks of illness were both significantly 
lowered in the vaccine group [table 2].
table 2. mean quality of life assessed by the pediatric asthma  
quality of life questionnaire (paqlq)
Qol scores* vaccine placebo p-value vaccine placebo p-value
 n=173 n=160  n=21 n=19
mean baseline  all weeks of illness influenza-positive weeks
total 5.54 5.43 0.35 5.87 5.47 0.15
activities 4.85 4.73 0.38 5.23 4.82 0.27
emotions 6.30 6.26 0.28 6.47 6.38 0.75
symptoms 5.24 5.10 0.72 5.69 5.03 0.08
mean differences** between baseline and  between baseline and
 all weeks of illness  influenza-positive weeks
total score –0.65 –0.76 0.19 –0.40 –1.00 0.02
activities –0.82 –1.00 0.14 –0.49 –1.31 0.02
emotions –0.35 –0.40 0.56 –0.21 –0.41 0.29
symptoms –0.81 –0.95 0.20 –0.52 –1.35 0.04
MID*** between baseline and   between baseline and 
 all weeks of illness  influenza-positive weeks
total score 50% 61% 0.06 48% 68% 0.22
activities 54% 64% 0.06 48% 79% 0.06
emotions 27% 26% 1.00 24% 26% 1.00
symptoms 52% 65% 0.01 43% 79% 0.03
* Scores range from 1-7, with higher scores indicating better quality of life.
** Negative differences, indicating a poorer quality of life during weeks of illness.
*** Proportion of patients with a negative difference of 0.5 points or more MID; minimal 
important difference.
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Symptom scores during weeks of illness
No differences were found between study arms for mean total or separate URT 
or LRT symptom scores and for symptom scores in influenza-related weeks or 
all weeks of illness irrespective of cause [table 3].
table 3.  mean respiratory tract symptom scores per day in children 
during weeks of illness
Mean upper respiratory tract (URT) symptom scores*
 All weeks of illness  Influenza-positive weeks
 vaccine placebo p-value vaccine placebo p-value
 n=176 n=166  n=22 n=20
runny or stuffy nose 0.91 0.85 0.43 0.97 0.85 0.60
sneezing 0.33 0.29 0.44 0.44 0.38 0.60
burning or watery eyes 0.13 0.15 0.74 0.26 0.20 0.68
sore throat 0.38 0.35 0.52 0.32 0.45 0.24
hoarseness 0.12 0.12 0.98 0.06 0.15 0.21
fever or shivering 0.22 0.21 0.86 0.41 0.43 0.82
headache 0.39 0.33 0.30 0.37 0.54 0.27
myalgia 0.07 0.07 0.89 0.07 0.10 0.67
total urt symptom score 2.56 2.37 0.37 2.91 3.13 0.69
Mean lower respiratory tract (LRT) symptom scores*
cough during the day 0.93 1.03 0.26 1.05 1.27 0.39
cough during the night 0.50 0.52 0.78 0.67 0.71 0.86
wheeze during the day 0.13 0.16 0.50 0.15 0.18 0.77
wheeze during the night 0.10 0.11 0.58 0.07 0.11 0.50
difficult breathing or
shortness of breath 0.39 0.42 0.56 0.32 0.64 0.06
total lrt symptom score 2.05 2.24 0.33 2.25 2.91 0.24
* Every separate score reached from 0 (absent) to 3 (severe).
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Spirometry
At inclusion, we acquired spirometric data of 682 children [table 1] and at 
baseline spirometric data of 669 children, 332 in the vaccine group and 337 in 
the placebo group [table 1]. Both baseline spirometry and spirometry during the 
weeks of illness were available for 455 of the 486 weeks of illness; in the remaining 
31 cases either one or both spirometric values were not available due to technical 
problems. No differences were found between vaccine and placebo for baseline 
spirometric values [table 1]. At the onset of influenza-positive periods we found 
a significant difference in FVC percentage predicted favouring the vaccine group 
[table 4], with a non-significant trend for improvement of FEV1.
table 4. data on spirometric parameters 
mean values vaccine placebo p-value vaccine placebo p-value
 n=172 n=157  n=21 n=20
values are mean (SD) all weeks of illness influenza-positive weeks
FEV1 1.95 (.75) 2.00 (.86) 0.63 1.77 (.82) 1.59 (.67) 0.31
% predicted 87 (17) 85 (17) 0.24 89 (22) 80 (20) 0.09
FVC 2.25 (.85) 2.31 (1.02) 0.60 2.06 (.52) 1.92 (.82) 0.53
% predicted 87 (16) 85 (17) 0.14 91 (18) 80 (19) 0.08
MEF50 2.36 (1.0) 2.38 (1.0) 0.87 2.08 (.50) 1.83 (1.0) 0.32
% predicted 81 (25) 79 (24) 0.69 78 (17) 75 (29) 0.66
MEF25 1.29 (.64) 1.33 (.71) 0.56 1.11 (.28) 0.98 (.56) 0.35
% predicted 88 (36) 88 (35) 0.86 83 (21) 82 (33) 0.92
differences* vaccine placebo p-value vaccine placebo p-value
 n=162 n=153  n=21 n=20
FEV1 –7 (13) –8 (12) 0.31 –4 (12) –12 (11) .06
FVC –5 (14) –6 (14) 0.34 –0 (12) –11 (15) .01
MEF50 –10 (16) –11 (20) 0.59 –11 (15) –17 (15) .17
MEF25 –8 (29) –10 (30) 0.37 –13 (22) –13 (19) .88
* Differences in % predicted comparing spirometry at baseline and during illness weeks 
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Daily symptom scores throughout the season
No differences were found for mean total daily scores on URT and LRT symptoms 
throughout the influenza season between the vaccine group and the placebo group 
[table 5] or for the number of days not fit to go to school or work because of 
those symptoms.
table 5.  mean respiratory tract symptom scores per day throughout 
the influenza season
 vaccine placebo
 n=344 n=344 
 mean symptom score* p-value
Upper respiratory tract (URT)
runny or stuffy nose 0.30 0.26 0.11
sneezing 0.12 0.10 0.29
burning or watery eyes 0.04 0.03 0.73
sore throat 0.07 0.06 0.10
hoarseness 0.03 0.03 0.64
fever or shivering 0.03 0.03 0.85
headache 0.10 0.09 0.41
myalgia 0.04 0.02 0.08
total URT symptom score 0.75 0.65 0.13
Lower respiratory tract (LRT)
cough during the day 0.25 0.23 0.61
cough during the night 0.11 0.11 0.98
wheeze during the day 0.04 0.04 0.85
wheeze during the night 0.03 0.04 0.39
difficult breathing or shortness of breath 0.13 0.14 0.90
total LRT symptom score 0.58 0.58 1.00
* Each separate score ranged from 0 (absent) to 3 (severe).
Detection of viruses
In 484 of 486 weeks of illness a throat swab was taken, one child on two occasions 
did not allow a throat swab to be taken. We detected viruses in 136 (28.1%) 
of 484 throat swabs (4 double infections), 41 times influenza A (8.5%), 3 times 
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influenza B (0.6%), 14 times corona (2.9%), 57 times rhinovirus (11.8%), 12 
times respiratory syncytial virus (2.5%) and 9 times miscellaneous viruses (1.9%) 
[table 6]. Detection rates were 37% for the vaccine group and 34% for the 
placebo group for 1999-2000, and 19% vs. 26% for 2000-2001, respectively. 
There were no significant differences in total detection rates or for separate viruses 
between the vaccine group and the placebo group.
table 6.  pathogens detected by either culture, IMMUNOFLUORESCENCE 
or pcr in throat swabs in reported periods
n=486 calls Placebo Vaccine Placebo Vaccine Total
 1999-2000 1999-2000 2000-2001 2000-2001
influenza H3N2 6 2 0 0 8
influenza H1N1 0 0 13 20 33
influenza B 0 0 2 1 3
rhinovirus 20 24 5 8 57
coronavirus  9 2 0 3 14
RSV 4 7 0 1 12
adenovirus 1 0 1 2 4
miscellaneous 3 2 3 1 9
no virus found 70 74 101 103 348
number of reported periods 111 112 124 139 486a
a Column does not add up to 486 because of four double infections and two absent throat swabs.
RSV: respiratory syncytial virus
Discussion
We found that influenza vaccination, compared to placebo, improved health-
related quality of life in asthmatic children in the weeks of illness in which 
influenza virus was detected in their throat swabs. This improvement was found 
for overall asthma-related quality of life as measured by the PAQLQ as well as 
for its symptoms and activities domains. The findings for the symptoms domain 
concur with the findings using the minimal important difference as an additional 
parameter, relevant for clinical practice. In illness weeks we also found a difference 
in FVC as percentage predicted favouring the vaccine group. However, in influenza-
positive weeks of illness no differences were found between the vaccine group 
and the placebo group for mean URT or LRT symptoms. Regarding all weeks 
of illness irrespective of their cause, no differences were found for mean URT 
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or LRT symptoms or for spirometric parameters. With regard to respiratory 
symptoms throughout the seasons, influenza vaccination did not reduce URT 
and LRT symptoms in asthmatic children.
That influenza vaccination in this analysis improves asthma related quality of 
life in weeks of illness is in contrast to our previous findings on influenza-related 
asthma exacerbations. Our earlier analysis showed no difference in the number, 
duration and severity of influenza-related asthma exacerbations as a result of 
vaccination.3
How can this discrepancy be explained? First, in our previous paper we defined 
exacerbations as episodes of LRT symptoms of 2 or more days with symptom 
scores above the median for that child preceded by at least 1 day at or below 
the median and followed by at least 2 days at or below the median. In this way 
less severe and supplemental symptomatology may have been ignored and hence 
a possible effect might have escaped attention. Secondly, the duration of the 
exacerbations may not exactly cover the weeks of illness in which we measured 
quality of life. Thirdly, the sensitivity of the PAQLQ for vaccine-related benefits 
may be higher than the diary symptom score list we used.8 This might well be 
the case, as questions on well-being, the use of more domains for measuring 
asthma, the greater scale range of the scores and the way of conducting the 
questionnaires by research nurses may detect changes that our simpler diary 
cards could not pick up. 
Our findings of no difference in the number of days with symptoms and the 
mean severity of symptoms throughout the seasons between study arms seem 
contradictory to the results of our first study that vaccination reduced the length 
of all asthma exacerbations, irrespective of their cause. A possible explanation 
is that the use of a threshold symptom score before telephoning, may have led 
to an under-detection of influenza and influenza related asthma exacerbations. 
However, when we consider all days with symptoms throughout the seasons, 
instead of restricting it to asthma exacerbations, differences disappear.
In our study baseline scores of the PAQLQ were relatively high, implying a better 
quality of life compared to other studies;15-17 these latter studies were, however 
performed in hospital-based populations. Children in our study probably had 
less severe asthma, because they were recruited via the GP. We found that weeks 
of illness were characterised by a reduction in the total PAQLQ score of 0.65 in 
the vaccine group and 0.76 in the placebo group, as compared to baseline. This 
reduction compares well with the decrease in symptoms of 0.65 points in children 
with mild and severe asthmatic episodes, which has been reported before.15 In 
the present study, compared with placebo, influenza vaccination improved the 
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total score on quality of life in influenza-positive periods by 0.6 points, which 
may be a meaningful improvement when considering the threshold for clinical 
relevance of 0.5 points for the MID. Other studies, also using the PAQLQ, found 
pre- and post-treatment improvements in total scores of 0.69 16 and 0.25 17 points. 
The PAQLQ has been reported to correlate with symptom scores and degree of 
asthma.15, 18, 19
With regard to spirometry we found a lower FVC in influenza-positive periods 
in the placebo group compared to the vaccine group. The fall in FVC could 
be a result of influenza infection, but may have been caused by inadequate 
spirometry performance of the children whilst being ill. This is supported by 
the fact that no difference was found on other spirometric indices. In weeks of 
illness irrespective of their cause, no significant differences were found between 
study arms in percentage of change in spirometry parameters, as an indicator of 
relevant airway obstruction in asthma. 
Using throat swabs, we detected viruses in 28.7% of the weeks of illness. 
Considering the viruses detected it is unlikely that an imbalanced distribution 
of viral infections confounded our results. Lower 20, 21 as well as higher 8, 22 
rates of detection have been reported in asthmatic children. The differences 
in detection rate between studies can be explained by differences in sample 
techniques, laboratory techniques, time frames used and natural fluctuations in 
the viruses that cause infection. 
Rhinovirus played the most important role in all these studies 8, 20-22 and were 
found in respectively 42%, 46%, 65%, and 66% of cases. In our study, rhinovirus 
was found in 41% of positive swabs. The incidence of influenza A and B varies 
with year and place. Of the 696 children in our study, 43(8.9%) had influenza 
detected by culture or PCR. In the above-mentioned studies 8, 20-22 influenza was 
detected in respectively 1%, 6.7% , 7.4% and 19.4% of participating children. In 
a recent study, Tsai et al.23 examined the relationship between clinical symptoms 
and respiratory infection using conventional laboratory methods in paediatric 
outpatients during three years (1997, 1998, 1999). In 35% of these cases one or 
more viruses were detected; influenza A was isolated in 5.5% and B in 2.6% of 
cases with acute respiratory tract conditions. In our study only small differences 
in the number and type of viral infections between vaccine group and placebo 
group were found.
What is the clinical relevance of the present findings? Vaccination rates in children 
with asthma are reported to be very low.24, 25 One of the reasons why physicians 
do not recommend influenza vaccination is disbelief in the positive effects of 
vaccination.26 Among patients, reasons not to obtain influenza vaccination are 
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doubts about the efficacy of influenza vaccine, fear of possible side-effects, and 
non-recommendation by their doctor.27, 28 As far as we know this is the first 
randomised placebo-controlled study to demonstrate beneficial effects of influenza 
vaccination in children with asthma. In our study influenza vaccination, compared 
with placebo, was associated with a relevant improvement in the quality of life of 
asthmatic children in the weeks of illness in which influenza virus was detected. 
However, our study had relatively low influenza-positive weeks of illness and 
could not detect any favourable effect of influenza vaccination on influenza-related 
asthma exacerbations and respiratory symptoms throughout the season. Hence, 
the question remains whether or not it is worth the effort to promote vaccination 
of all asthmatic children aged 6-18 years in general practice. 
Therefore, to justify routine influenza vaccination in asthmatic children, we 
strongly recommend that further randomised placebo-controlled trials be carried 
out to assess the clinical effectiveness as well as the cost-effectiveness of influenza 
vaccination in children with asthma. 
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7. General discussion
The studies reported in this thesis were performed to collect the best available 
evidence for the burden of disease from influenza in children and to reliably assess 
the effectiveness of influenza vaccination in children with asthma. 
To gain overview of the burden of disease due to influenza in children we performed 
a systematic review on the incidence of influenza and its related illness [chapter 2]. 
 
To provide direct evidence for the protective effectiveness and adverse effects 
of influenza vaccination in children with asthma we performed a double blind 
placebo-controlled trial into the effectiveness of influenza vaccination on asthma 
symptoms [chapter 3, 4, 5, 6].
Current state of affairs and questions to be asked
Asthma is nowadays seen as a disease of chronic inflammation of varying 
degrees of severity instead of solely a disease of reversible airway obstruction. 
Treatment has progressed along with the growing knowledge of the underlying 
pathophysiological mechanisms.1 With adequate treatment, consisting of a 
combination of maintenance and rescue medication, patients nowadays can lead 
a normal life and suppress the asthmatic symptoms following common airway 
infections.2 This treatment is at direct disposal of patients and their caretakers and 
there is no indication that its efficacy is influenced by the antigenic characteristics 
of the influenza virus. 
In children, asthma is in absolute and relative numbers the most important 
chronic disease. The reason to vaccinate asthmatic children against influenza 
is the prevention of exacerbations of upper respiratory tract (URT) and lower 
respiratory tract (LRT) symptoms, i.e. asthma symptoms, and the prevention of 
more rare complications, such as pneumonia. A diagnosis of asthma is the most 
common reason for which children should receive influenza vaccination.3 
Most Western guidelines advise to vaccinate patients with asthma against 
influenza,4, 5 although we lack solid evidence from randomised trials for the 
preventive effect on clinical endpoints, i.e. based on symptoms of asthma.6 
When advocating a preventive activity, like influenza vaccination in children with 
asthma, a set of fundamental questions has to be answered. For this purpose, 
I adapted Demicheli’s questions with respect to mass vaccination for influenza,7 
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which obviously derive from the criteria used for mass screening.8 
• Is the condition or the disease to be prevented important? 
•  Do we know enough about the incidence, the natural history and the burden 
of this disease to reasonably forecast the likely impact of immunization?
•  Does the vaccine work? (That is, is it effective in preventing clinical cases of 
influenza related asthma exacerbations?)
•  Did the vaccine work in our study? (That is, was it effective in preventing 
clinical cases of influenza related asthma exacerbations?)
•  Is the vaccine safe and acceptable? (That is, does it have adverse effects in 
children with asthma and, if so, are they localized or systemic and of short 
or long duration? Does the vaccine make the best use of resources available 
compared with doing nothing or other preventive or therapeutic options? 
I will reflect on these questions in the light of the evidence that is now available 
upon completion of our study. Finally I will make suggestions for altering the 
guidelines and future research to be done.
Is the condition or the disease to be prevented important?
Influenza is one of the common respiratory tract infections in children9, 10 and, 
according to the World Health Organisation, a yearly public health problem in 
children as well as in the community at large.11 Every season, after the virus has 
appeared and a rise in influenza like illnesses (ILI) has been assessed, influenza 
centres worldwide provide information on influenza activity and its presumed 
impact.12 Many viruses, however, can be responsible for influenza like illnesses13-15 
and the true incidence of influenza proper and its associated illness is still 
unclear.
Because of different subtypes of the virus and its constant antigenic drift, acquired 
immunity is usually only partial and therefore the population will always to 
a greater or lesser extent be susceptible. Thus, to gain an accurate view on 
the overall impact of influenza one obviously should take several seasons into 
consideration.
Preferably, for influenza, laboratory proof for the presence of influenza virus should 
coincide with symptomatic disease.16 Yet, in reports on the impact of influenza 
outbreaks these data are often lacking. Instead, isolated serologic incidence rates, 
rates of influenza like illness9, 12, 17-20 and the occurrence of complications are used 
as a proxy.21-24 In these studies hard confirmation of ‘influenza illness’ on the 
individual level is not possible.
Besides, reports on the burden of disease for influenza (e.g. hospitalisations) are 
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often not related to a properly described population at risk. Nevertheless, the 
clinical, societal and economic impact of non-pandemic influenza seems to be taken 
for granted and there is hardly any discussion on these basic assumptions. 
Children with asthma are reported to be at a higher risk for complications 
than adults, although no mortality was reported.21-23, 25 Since these studies were 
retrospective in design or the population at risk was not well-defined, assumptions 
on complications of influenza infections in asthmatics are based on indirect 
evidence. Therefore the information reported in these studies is mostly presented 
in general terms like “excess health care use” in influenza seasons, regarding for 
instance hospitalisations or prescriptions for asthma.
In children with asthma, influenza may cause upper respiratory tract infections 
that often precede exacerbations. Furthermore it is the only respiratory disease 
for which vaccines are widely available. 
However, because far more asthma exacerbations and complications of asthma 
in children are caused by other viruses, mostly rhinoviruses, the relative impact 
of influenza on disease in asthmatic children is limited.26, 27
I conclude that, although the importance of influenza in asthmatic children is 
frequently stressed, one can question the reliability of the hitherto reported 
evidence for that belief. Apart from that, the believed importance of influenza 
obviously relies on the history of pandemics and fear of a new pandemic.28
Do we know enough about the incidence, the natural history and the burden of 
this disease to reasonably forecast the likely impact of immunization?
To gain overview of the available hard evidence for the incidence and the burden 
of disease due to influenza in children we performed a systematic literature 
review.
Incidence of influenza and related illness
Although incidences in specific seasons can peak up to 46%, we found, looking 
at studies which measured the occurrence of influenza and its related illness over 
a prolonged time period, the average seasonal incidence of influenza A and B 
to be 4.6% in children 0-19 years and 9.5% in children <5 years.19, 29 In most 
of the studies, symptoms that triggered laboratory measurements as well as 
symptoms assessed in the course of episodes usually were characterised as mild. 
Convalescence was reported to be rapid30 or within a school absence of two 
days,31 whereas the duration of the illness was reported to be between three32 
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and 10-13 days.19 Mortality as an outcome of influenza illness in children was 
not found in these studies although case reports sometimes link cases of death in 
children to influenza infection.33 Hospitalisation rates for influenza widely differ 
in the long term studies included and range from 29 per 100000 children <16 
years of age34 to 230 per 100,000 children <5 years of age.29
Incidence of respiratory symptoms due to influenza in children with asthma
We found only two studies that assessed the incidence of influenza related 
respiratory illness in asthmatic children while confirming the presence of influenza 
by culture. This ‘hard’ incidence was found to be 11.5 % for both influenza A 
and B in 48 unvaccinated children (aged 2-14 years) under surveillance of an 
asthma clinic in Japan.35 Three children (6%) were hospitalised for pneumonia. 
In another, community based, study 18% of schoolchildren (aged 9-11 years) had 
influenza related asthma exacerbations but no serious complications occurred.26 
Asthma exacerbations as well as episodes of upper respiratory tract symptoms 
lasted about 7 days and did not differ between viruses detected. In the placebo 
arm of our trial in asthmatic children the incidence of laboratory confirmed 
influenza-related asthma exacerbations was found to be 5%, again no serious 
complications occurred.36 Influenza related upper respiratory tract episodes lasted 
8 days whereas influenza related asthma exacerbations lasted 11 days.
In conclusion, the incidence of influenza related asthma exacerbations in children 
and its complications have not been extensively investigated. Incidences for 
children with asthma as reported here were between 5-18%. Although one 
small study, with children under the surveillance of an asthma clinic, found a 
hospitalisation rate of 6%, no complications were found in the above mentioned 
community based study on asthmatic children nor in our study that recruited 
patients in general practice. Regarding the long term overall incidence for influenza 
related illness in children of 4.6% (0-19 years) and 9.5% (0-5 years) and the mild 
clinical picture of the disease in healthy and asthmatic children one can question 
the likely impact of immunisation in asthmatic children.
Does the vaccine work?
Is influenza vaccine effective in preventing clinical cases of influenza related 
asthma exacerbations? A systematic review of randomised trials of the effects of 
influenza vaccine in healthy adults showed that inactivated parenteral vaccines 
indeed had an efficacy of 70% (95% confidence interval [CI] 56% to 80%) in 
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reducing serologically confirmed cases of influenza. But when using symptom based 
outcomes, i.e. clinical cases of influenza, the vaccine had only an effectiveness of 
25% (95% CI 13% to 35%).37 These figures on efficacy were recently confirmed 
in another meta-analysis.38 A systematic review of randomised trials in asthmatics, 
children as well as adults, asserted that uncertainty remains about the degree of 
protection vaccination affords against influenza related asthma exacerbations.6
Recapitulating, the vaccine works but the degree of protection against clinical 
outcomes is meagre for healthy subjects and unknown in asthmatics.
Did the vaccine work in our study?
Clinical cases of influenza in asthmatic children
When designing the study we firstly came across the problem that there is no 
universal definition of an asthma exacerbation, which in my opinion is the most 
obvious symptom-based complication of influenza in asthma patients. In the 
available literature different parameters are used, e.g. the prescription of antibiotics 
or prednisone, visit to a physician for respiratory complaints, hospitalisation and 
spirometric data. Secondly, URT and general symptoms of influenza infection 
often precede LRT symptoms typical for an asthma exacerbation. Thus to relate 
infection to an asthma exacerbation not only lower, but also upper respiratory 
tract symptoms should provoke the sampling of influenza virus. Thirdly, for 
the detection of influenza a symptom-based threshold should be set to identify 
clinically relevant episodes, preventing unnecessary inconvenience of participants 
and taking into account the available resources, including research personnel.
After studying the literature, we found one method that met these three conditions 
and was used before by Johnston.26 In short, an asthma exacerbation was defined 
as a period of two ore more days with LRT symptoms above the median for that 
child. For URT as well as LRT symptoms a threshold that triggered culturing 
influenza was defined. A simple diary with a symptom score list was used for 
participants to be filled in daily and provided all the necessary data. 
Besides respiratory symptoms per se as a clinical relevant outcome of asthma we 
used a health related questionnaire, which measures changes in quality of life 
because of asthmatic symptoms on a physical, emotional, and social level, as an 
endpoint.39, 40 For this reason the Dutch version of the 23-item Pediatric Asthma 
Quality of Life Questionnaire (PAQLQ) as designed by Juniper was validated.
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Acquired immunity
In designing this study on the effectiveness of influenza vaccination in general 
practice we did not exclude children that acquired immunity by vaccination or 
infection in previous seasons to mimic the preventive effect of influenza as applied 
routinely in general practice.
Assumptions
Several assumptions were made to determine sample size. We wanted to be able 
to detect a 50% reduction in the number of asthma exacerbations caused by 
influenza virus with α=0.05 and β=0.2 (two-sided test). Reported infection rates, 
mainly based on serological data, have usually been in the range of 20-40%.18, 19 
We assumed a 30% incidence and that 50% of infected children would react with 
an exacerbation. Thus we aimed at a total number of 600 children for whom 
complete data would be available, i.e. 300 children per season. This would allow 
us to show 50% reduction when 15% of the children in the placebo group would 
show influenza-related exacerbations. In the first season, we obtained data from 
297 children. However, only six influenza positive throat swabs in the placebo 
group were found, which is much less than we expected (22). Because of this 
we seriously considered to stop the study. After careful consideration of various 
scenarios we decided to continue and make an effort to include more participants 
during the second season. We aimed at recruiting as many children as possible 
with the available personnel, and ended up with exactly 400 children, giving 
a total of 697 children. Because the number of dropouts was surprisingly low, 
altogether 688 children completed the study.
We investigated two influenza seasons 1999-2000 and 2000-2001, in which 
H3N2, H1N1 and B subtypes occurred and ended up with 42 influenza related 
asthma exacerbations, 24 in the placebo group and 18 in the vaccine group, a 
difference of 33% favouring placebo (31% after adjustment for confounders; 95% 
confidence interval, –34% to 161%). Because the incidence of 5% influenza related 
asthma exacerbations in the placebo group is much lower than the presumed 
15%, questions on power calculations seem inevitable. Though, the issue of 
power calculation has been raised and debated before,41, 42 power is not an issue 
anymore after a study has completed. I quote Altman: “There is [.....] little merit 
in calculating the statistical power once the results of the trial are known; the 
power is then appropriately indicated by confidence intervals”.43
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Subtypes of influenza
We did not aim to study effectiveness for different influenza subtypes present in 
the vaccine. However, we used a trivalent composition of influenza A (H1N1 and 
H3N2) and influenza B strains and there may be differences in their protective 
effectiveness. Several other factors can influence clinical effectiveness such as 
the phylogenetic distance between the wild virus and the strains in the vaccine, 
acquired immunity, different incidences and difference in virulence between 
seasonal occurring subtypes. I am of the opinion that asthmatic children are 
vaccinated to prevent overall influenza infection and influenza related illness 
regardless of these factors and think that effectiveness of the vaccine should 
be measured accordingly. Moreover, in my opinion clinical effectiveness of 
influenza vaccination should be measured over several seasons to value its overall 
effectiveness.
Results
In our randomised trial no effect on the number, duration and severity of influenza 
related asthma exacerbations was found. Nonetheless an effect on the duration 
of all asthma exacerbations, irrespective of cause, of 0.8 days as well as discrete 
effects on health related quality of life in influenza related weeks of illness 
favouring the vaccine group was found. However, in influenza positive weeks 
of illness no differences were found between the vaccine group and the placebo 
group for mean URT or LRT symptoms or spirometry values. Regarding all 
weeks of illness, irrespective of their cause, no differences were found for mean 
URT or LRT symptoms or for spirometric parameters. For respiratory symptoms 
throughout the seasons, influenza vaccination did not reduce URT and LRT 
symptoms in asthmatic children. 
Our conclusion is that on the primary outcome measure, the number of influenza 
related asthma exacerbations, the 95% confidence interval of the results from 
our study excludes a protective effectiveness of influenza vaccination of 35% 
or more. Except for a discrete difference for quality of life in influenza positive 
weeks no other benefits of vaccination were found.
Is the vaccine safe and acceptable? (That is, does it have adverse effects in 
children with asthma and, if so, are they localized or systemic and of short or 
long duration?)
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Recent studies did not confirm that influenza vaccination exacerbates asthma 
defined as complications such as hospitalizations and emergency department 
visits.44, 45
In our study we considered local and systemic symptoms, including URT and LRT 
symptoms, in the first week after influenza vaccination, as adverse effects. Except 
for one LRT symptom (frequency of cough at daytime) favouring placebo in the 
first season, we did not find an indication that influenza vaccination provokes 
asthma exacerbations.
It is clear that safety and tolerability of influenza vaccination in asthmatics are 
well established by previous research. Our findings using respiratory and other 
symptoms strongly support the presumed safety. Influenza vaccination can thus 
be given safely to children with asthma.
Does the vaccine make the best use of resources available compared with doing 
nothing or other preventive options?
Role of influenza incidence and clinical effectiveness of parenteral influenza 
vaccine
When determining cost-effectiveness of influenza vaccination several seasons 
should be considered and included in a cost-effectiveness analysis. However, an 
overall incidence of influenza related illness between 4.6-9.5% as found before 
or 5% as found in the placebo arm of our study is a difficult starting point. 
Using this incidence, regardless of clinical relevance and assuming protective 
effectiveness of vaccination to be 100%, 22 children (0-19 years) 11 children 
(0-5 years), respectively 20 children (6-18 years) have to be vaccinated in order 
to prevent influenza related illness in one child. Because the effectiveness of 
influenza vaccination is lower than 100% and clinical relevance has to be taken 
into account, the numbers needed to treat will be higher than calculated here. 
For instance, in healthy subjects, a clinical effectiveness of the vaccine of just 
25% was found.37 When extrapolating, this quadruples the above mentioned 
numbers needed to treat.
In asthmatics there is no evidence about the degree of protection vaccination 
provides against influenza related asthma exacerbations.6 In our own study, taking 
the most favourable boundary of the 95% CI, effectiveness will not be higher 
than 35%. When assuming a protection rate of 35%, vaccinating 57 children 
with asthma could prevent only one influenza related asthma exacerbation.
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Other preventive options
Intranasal vaccines
In the past years intranasal influenza cold adapted live attenuated vaccines have 
been developed and tested. Besides the less invasive route of administration, the 
triggering of the mucosal Ig-A defence system may proof to be a potential benefit. 
However, serologically as well as clinically, intranasal vaccines have been reported 
to be less effective than parenterally administered vaccines.37
Although intranasal vaccines are generally well tolerated in children and 
adolescents with asthma no evidence in randomised trials was found for its 
clinical effectiveness in asthmatics.6
Antiviral agents
Apart from influenza vaccination as preventive treatment for influenza there are 
antiviral agents that can be used for this purpose.
Amantadine and rimantadine are effective in the treatment and prophylaxis of 
influenza A, but these drugs are not widely used due to a lack of knowledge of 
their potential value and concerns about possible adverse effects.46
The more recently developed neuraminidase inhibitors zanamivir and oseltamivir 
are safe and were clinically effective in healthy children with a clinical or laboratory 
diagnosis of influenza A and B. However, efficacy in ‘at risk’ children, such as 
asthma, remains to be proven and its role in the prevention of influenza related 
illness in asthmatic children is currently not established.47
Regarding cost-effectiveness, the balance for antivirals in comparison with 
vaccination is rather unfavourable.48
Inevitably one must conclude that for children with asthma cost-effectiveness for 
vaccination will be difficult to attain. Other preventive options, which could be 
used for children with asthma, lack the necessary evidence on clinical endpoints. 
Furthermore for some of the mentioned alternative options there are doubts 
about cost-effectiveness.
Conclusion and options for future research
Summarizing, I conclude that, given the available information on the effectiveness 
of airway medication; the low overall incidence of influenza; the absence of direct 
evidence for serious complications of influenza infection in asthmatic children; 
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the absence of evidence for the clinical effectiveness of influenza vaccination in 
asthmatic children; the absence of adverse effects of influenza vaccination and 
the doubts about cost-effectiveness of this preventive intervention in asthmatic 
children, guidelines on influenza vaccination should be revised and, despite the 
safety of vaccination, should reconsider the advice to vaccinate children with 
mild to moderate asthma. 
Future research should first of all focus on long term observational research, 
spanning more seasons, to determine the real impact of influenza in children with 
and without asthma. Whereas sentinel stations, in cooperation with national 
influenza centers, nowadays provide information on the number of influenza 
like illnesses per number of physicians consultations or at a population level, 
they could deliver information based on culture confirmed illness and the 
burden of disease due to influenza in a well defined population at risk. Secondly, 
experiments in which populations in certain regions, covered by sentinel stations, 
are asked to participate in vaccination trials, could measure the effect of influenza 
vaccination in the different age or disease categories, including asthma, for which 
vaccination is advocated but for which insufficient evidence for its effectiveness 
is currently available. In this way, the update of recommendations can be guided 
by medicine-based evidence49 which in turn will improve the effectiveness of 
recommendations.50
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Summary
Every year, outbreaks of influenza appear across the world and cause substantial 
morbidity and mortality in the general population, particularly in persons with 
underlying conditions including asthma. Because the influenza virus changes 
constantly, man’s acquired immunity is usually only partial and therefore the 
population will always to a greater or lesser extent be susceptible.
In asthmatics, influenza causes upper respiratory tract infections that frequently 
trigger exacerbations. Large population-based studies have estimated the morbidity 
and the risk of developing clinical complications in people with asthma. During 
influenza periods, hospitalisation, drug prescriptions and visits to physicians 
increase, and asthma exacerbations and pneumonia have been reported as the 
most common complications. Children with asthma are at a higher risk for 
complications than adults. Reasons to vaccinate asthmatics are the prevention of 
influenza-related illness and complications, including asthma exacerbations and 
death. However, the protective effect of influenza vaccination in asthmatic patients 
is still disputed. So far no unequivocal beneficial effect of influenza vaccination 
in asthmatics was found in observational and experimental studies in the sense 
of reduction of asthma exacerbations and of other complications.
Although opinions on the clinical effectiveness of influenza vaccination in 
asthmatic patients are currently based on consensus and indirect evidence, the 
guidelines of most Western countries advise to vaccinate patients with asthma. 
As a result, in asthma care, influenza vaccination is considered to be a cornerstone 
for quality of care.
Despite these recommendations only a minority of asthma patients is vaccinated 
worldwide. Reasons for this are fear among patients that vaccination could cause 
influenza, and doubts about benefits and effectiveness of influenza vaccination 
amongst physicians and patients.
Aim of this thesis is to provide evidence to either support or modify the policy 
of vaccinating asthmatic patients as is described in most western guidelines. 
I will focus on children, because in children asthma is the most important reason 
for influenza vaccination and asthma is the most frequent chronic disease in 
childhood. 
In chapter 2 we report on the available knowledge of the incidence of influenza, 
the natural course and the burden of disease. Incidence figures are a prerequisite 
to reliably forecast the impact of preventive measures for influenza and calculate 
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the number needed to treat in order to prevent one additional case of influenza. 
Likewise, incidence figures are also needed to estimate the number of participants 
for preventive or therapeutic trials. 
We conducted a systematic review to estimate the incidence of influenza and 
concomitant morbidity and mortality in children 0 through 19 years (0-19 
years). We searched for observational studies and placebo or non treated arms 
of experimental studies for information on laboratory proven influenza illness.
From a total of 2758 papers, 356 papers were reviewed on the basis of abstract or 
title. Sixteen papers were added searching the reference list of these papers. Finally 
28 studies met inclusion criteria. They showed a varying incidence of influenza 
with figures up to 46%. However, when looking at two long term observational 
studies and averaging seasonal fluctuations, the overall incidence of influenza 
in children was found to be between 5% (children aged 0-19 years) and 9.5% 
(children aged 0-5 years) per year. Serious morbidity was seldom reported. In 
the studies selected we found no cases of mortality. 
Our conclusion is that, given the average incidence for influenza found, the self-
limited character of the disease, the mild associated morbidity and the rare cases 
of mortality in children, one can question if influenza in children at a population 
level is a major public health problem. As a result of this outcome we advise that 
preventive strategies for children should be reconsidered. When investigating 
preventive strategies for influenza one should be led by the average incidence 
and include more seasons.
In chapters 3-6 we present various results of our randomised double-blind 
placebo-controlled trial in 696 children with asthma, aged 6-18 years. Parenteral 
vaccination with inactivated influenza vaccine or placebo took place approximately 
November 1st, and children were followed until April 1st of the next year. Local 
and systemic symptoms, possibly as a result of vaccination, and airway symptoms 
were reported in a diary. Symptoms scored during the first week after vaccination 
were considered to be adverse effects of the vaccination. When symptom scores 
reached a predefined level, a pharyngeal swab was taken and spirometry was 
performed. One week later a quality of life questionnaire was administered. 
Primary outcome was the number of asthma exacerbations associated with 
virologically proven influenza infection. Three hundred forty-nine children were 
assigned placebo, and 347 were assigned vaccine.
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In chapter 3, we address the adverse effects of influenza vaccination, especially 
on asthma. Because there is a constant debate that influenza vaccination may 
provoke an asthma exacerbation, a decisive answer to these doubts may affect 
vaccination rate.
During the first week after vaccination, participants recorded local, influenza 
like and asthma symptoms as well as use of medication, health care use and 
absenteeism. As reported in previous studies, vaccine recipients reported redness 
and stiffness of the arm much more often than placebo recipients. For symptoms 
of influenza like illness, fever, headache and myalgia showed smaller though 
significant differences during the first season, as did hoarseness during the second 
season, all favouring placebo. These differences may be an expression of the 
difference between strains used in the vaccine during the two seasons or may be 
a result of a difference between populations studied in the two influenza seasons. 
Except for cough during the day in the first season, favouring placebo, there were 
no differences indicating that vaccination exacerbates asthma. We conclude that 
influenza vaccination does not seem to exacerbate asthma and can be given safely 
to asthmatic children.
In the literature there is little evidence that influenza vaccination reduces asthma 
exacerbations. In chapter 4 we report the main results of our randomised double-
blind placebo-controlled trial in asthmatic children regarding the preventive effect 
of influenza vaccination on clinical illness, notably asthma exacerbations.
Children reported, as described above, airway symptoms in a diary. When symptom 
scores reached a predefined level, a pharyngeal swab was taken. Primary outcome 
was the number of asthma exacerbations associated with virologically proven 
influenza infection. We considered a reduction in asthma exacerbations of at 
least 50% as clinically relevant. Three hundred forty-nine children were assigned 
placebo, and 347 were assigned vaccine. Pharyngeal swabs positive for influenza 
were related to 42 asthma exacerbations, 24 in the vaccine group and 18 in the 
placebo group, a difference of 33% favouring placebo (31% after adjustment 
for confounders; 95% confidence interval, –34% to 161%). Influenza-related 
asthma exacerbations were of similar severity in both groups; they lasted 3.1 
days shorter in the vaccine group (95% confidence interval, –6.2 to -0.002 days, 
p=0.06). We conclude that influenza vaccination did not result in a significant 
reduction of the number, severity, or duration of asthma exacerbations caused 
by influenza. We think additional studies, using influenza proven clinical illness 
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as an endpoint, are warranted to justify routine influenza vaccination of children 
with asthma.
Health-related quality of life (physical, social and emotional impairments) should 
be an important measure in evaluations of the management of childhood asthma. 
Therefore, in chapter 5, the Pediatric Asthma Quality of Life Questionnaire 
(PAQLQ), a questionnaire in English to define quality of life in asthmatic children, 
is validated for the Dutch translation.
We assessed psychometric properties, responsiveness, and longitudinal and cross-
sectional construct validity of the Dutch PAQLQ version. The study group 
consisted of 238 children (6–18 years) with asthma, a subset of children from our 
trial on influenza vaccination, with complete respiratory symptom diaries in the 
course of one winter season; each child had one (or more) PAQLQ measurement(s) 
concerning one (or more) week(s) with relatively many symptoms (n=238). Each 
child also had one PAQLQ measurement concerning another week with relatively 
few symptoms. The PAQLQ scores of these weeks were compared. Additionally, 
in a subgroup of the study group that had experienced two or more ‘weeks with 
many symptoms’ (n=101), we compared the PAQLQ scores for two different 
weeks with many symptoms of these children. All Cronbach’s α’s of the PAQLQ 
total score and domains were above 0.70, except for Activities (α=0.54), indicating 
that the internal consistency of the questions in the questionnaire is moderate 
to good. Mean PAQLQ scores were significantly different (p <0.01; n=238) 
between one week with few symptoms and another week with many symptoms. 
Contrarily, in the subgroup of children with PAQLQ measurements regarding 
more than a week with many symptoms (n=101), mean PAQLQ scores did 
not differ significantly (p >0.05) between a week with many symptoms and 
another week with many symptoms. These results indicate responsiveness of the 
instrument. Changes in lower respiratory tract symptoms, indicative of asthma 
severity, correlated better with changes in PAQLQ scores than changes in upper 
respiratory tract symptoms, which supports the longitudinal and cross-sectional 
construct validity. The assessed properties of the translation into Dutch were 
similar to those originally established for the PAQLQ in Canada. This study 
showed that the Dutch PAQLQ has adequate psychometric properties, excellent 
responsiveness, and that its longitudinal and cross-sectional construct validity 
is supported. As this questionnaire has been translated and validated in several 
languages it is an excellent tool for international and trans-cultural asthma 
research.
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In chapter 6 we show the effect of influenza vaccination on the well being of 
asthmatic children.
Using PAQLQ, we measured the effects of influenza vaccination on physical, 
emotional and social impairments in asthmatic children. Supplementary we 
assessed whether influenza vaccination has an effect on the corresponding 
respiratory symptoms and spirometric parameters as well as on all their symptoms 
throughout the season.
Compared to placebo, vaccination improved health-related quality of life in the 
weeks of illness related to influenza-positive swabs. However, no effect was found 
for respiratory symptoms recorded in the diaries during those weeks. Similarly, no 
differences were found for quality of life in all weeks of illness or for respiratory 
symptoms throughout the seasons.
Our conclusion is that influenza vaccination has a moderate beneficial effect on 
quality of life in influenza-positive weeks of illness in children with asthma.
In chapter 7 we reflect on our findings and conclude that, given the available 
information on the effectiveness of airway medication; the low overall incidence 
of influenza; the absence of direct evidence for serious complications of influenza 
infection in asthmatic children; the absence of evidence for the clinical effectiveness 
of influenza vaccination in asthmatic children; the absence of adverse effects of 
influenza vaccination and the doubts about cost-effectiveness of this preventive 
intervention in asthmatic children, guidelines on influenza vaccination should 
be revised and, despite the safety of vaccination, should reconsider the advice 
to vaccinate children with mild to moderate asthma.
Future research should first of all focus on long term observational research, 
spanning more seasons, to determine the real impact of influenza in children with 
and without asthma. Whereas sentinel stations, in cooperation with national 
influenza centres, nowadays provide information on the number of influenza like 
illnesses per number of physicians consultations or at a population level, they 
could deliver information based on culture confirmed illness and the burden of 
disease due to influenza in a well defined population at risk. Secondly, experiments 
in which populations in certain regions, covered by sentinel stations, would be 
asked to participate in vaccination trials, could measure the effect of influenza 
vaccination in the different age and disease categories, including asthma, for which 
vaccination is advocated but for which insufficient evidence for its effectiveness 
is currently available. In any case, experimental designs should take symptoms 
of patients on an individual level and symptom based measurements, such as 
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PAQLQ, as an outcome. In this way, the updating of recommendations can be 
guided by medicine-based evidence wich in turn may improve the effectiveness 
of recommendations. 
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Samenvatting
Over de gehele wereld zijn er ieder jaar uitbraken van influenza die substantiële 
morbiditeit en mortaliteit teweeg brengen onder de bevolking, in het bijzonder 
bij personen met een onderliggend lijden zoals astma. Omdat het influenzavirus 
constant verandert is de bescherming die men na een infectie opbouwt slechts 
gedeeltelijk, hierdoor zal de bevolking altijd in meerdere of mindere mate 
ontvankelijk zijn voor het influenzavirus.
Een influenza-infectie veroorzaakt bij patiënten met astma een ontsteking 
van de bovenste luchtwegen die vaak een astma-aanval uitlokt. Er zijn grote 
studies gedaan waarbij onderzocht is hoeveel ziekte er veroorzaakt wordt door 
influenza en wat de kans is op klinische complicaties bij patiënten met astma. 
Het aantal ziekenhuisopnames, medicijnvoorschriften en bezoeken aan een arts 
stijgt tijdens griepperiodes en als meest voorkomende complicaties treden astma-
aanvallen en longontsteking op. Kinderen met astma lopen een groter risico 
op complicaties dan volwassenen. Patiënten met astma worden gevaccineerd 
ter voorkoming van door influenza veroorzaakte ziekte en de bijbehorende 
complicaties, waaronder astma-aanvallen en overlijden. Het beschermende effect 
van influenzavaccinatie is echter nog steeds onderwerp van discussie. Tot nu toe 
is in observationele en experimentele studies niet ondubbelzinnig aangetoond 
dat influenzavaccinatie het aantal astma-aanvallen of andere complicaties van 
influenza gunstig beïnvloedt.
Hoewel de ideeën over de klinische effectiviteit van influenzavaccinatie bij 
patiënten met astma op dit moment zijn gebaseerd op consensus en indirect bewijs, 
wordt in de richtlijnen van de meeste Westerse landen geadviseerd patiënten met 
astma te vaccineren tegen influenza. Griepvaccinatie wordt dan ook gezien als 
een hoeksteen van de kwaliteit van de zorg bij patiënten met astma.
Ondanks de genoemde aanbevelingen wordt wereldwijd slechts een minderheid 
van de astmapatiënten gevaccineerd. Bij patiënten bestaat er angst dat vaccinatie 
juist influenza veroorzaakt en bij patiënten én artsen blijven er twijfels bestaan 
over de voordelen en de effectiviteit van influenzavaccinatie.
Dit proefschrift wil bewijs leveren ter ondersteuning of aanpassing van het 
in de meeste westerse landen gevoerde beleid om patiënten met astma te 
vaccineren tegen influenza. Ik beperk me daarbij tot kinderen: bij hen is astma 
de meest voorkomende chronische ziekte en tevens de belangrijkste reden voor 
griepvaccinatie.
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In hoofdstuk 2 beschrijven we de kennis die op dit moment aanwezig is met 
betrekking tot de incidentie, het natuurlijke verloop en de ziektelast van 
influenza.
Incidentiecijfers zijn onontbeerlijk om de gevolgen van preventieve maatregelen 
tegen influenza te kunnen voorspellen en te berekenen hoeveel mensen gevaccineerd 
moeten worden om één geval van influenza te voorkomen. Deze cijfers zijn 
ook een voorwaarde om het aantal benodigde deelnemers voor preventieve of 
therapeutische trials te kunnen schatten.
We voerden een systematische review uit om te bepalen wat de incidentie van 
influenza en de daardoor veroorzaakte morbiditeit en mortaliteit is bij kinderen 
van 0 tot en met 19 jaar (0-19 jaar). Daarbij zochten we naar informatie over, 
middels laboratoriumonderzoek bewezen, door influenza veroorzaakte ziekte in 
observationele studies en experimentele studies met een placebo arm of een arm 
waarin geen behandeling plaatsvond.
Van in totaal 2758 artikelen werden 356 artikelen, op basis van het abstract of 
de titel, door de beoordelaars besproken. Zestien artikelen werden toegevoegd 
op basis van de referentielijsten van deze artikelen. Uiteindelijk voldeden 
28 artikelen aan de inclusiecriteria.
De incidentiecijfers van influenza varieerden nogal met als hoogste cijfer een 
incidentie van 46%. Als we echter kijken naar de twee gevonden langjarige 
observationele studies, bleek de gemiddelde jaarsincidentie van influenza bij 
kinderen te liggen tussen 5% (0-19 jaar) en 9.5% (0-5 jaar). Ernstige morbiditeit 
werd zelden beschreven en in de geselecteerde studies werd mortaliteit niet 
genoemd.
Als we kijken naar de gemiddelde incidentie van influenza, het zichzelf beperkende 
karakter van de ziekte, de milde bijkomende morbiditeit en de zeldzaamheid 
van mortaliteit bij kinderen, is het de vraag of influenza bij kinderen op 
bevolkingsniveau een groot maatschappelijk gezondheidsprobleem is. Op basis van 
onze uitkomsten is ons advies de huidige preventieve maatregelen te heroverwegen. 
Daarnaast vinden we dat bij onderzoek van preventieve strategieën voor influenza 
men zich moet laten leiden door de gemiddelde incidentie én meerdere seizoenen 
in beschouwing moet nemen.
In hoofdstuk 3-6 presenteren we de resultaten van ons gerandomiseerde 
dubbelblinde placebogecontroleerde onderzoek bij 696 kinderen met astma in 
de leeftijdsgroep van 6 tot en met 18 jaar. Rondom 1 november ontvingen de 
kinderen een injectie met geïnactiveerd influenzavaccin of placebo, de kinderen 
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werden daarna gevolgd tot 1 april van het daaropvolgende jaar. Zij noteerden 
locale en algemene klachten ten gevolge van de vaccinatie en luchtwegklachten 
in een dagboekje. De genoteerde klachten in de eerste week beschouwden we als 
bijwerking van de vaccinatie. Als, na de eerste week, de gescoorde luchtwegklachten 
een van tevoren afgesproken grens bereikten, werd een keelwat afgenomen 
en vond een longfunctiemeting plaats. Een week later werd een kwaliteit van 
levenvragenlijst afgenomen. Van de deelnemende kinderen ontvingen 349 het 
placebovaccin en 347 het influenzavaccin.
In hoofdstuk 3 onderzochten we de bijwerkingen van griepvaccinatie vooral met 
betrekking tot de gevolgen voor het astma. Omdat er al lang discussie is over 
de vraag of influenzavaccinatie een astma-aanval kan uitlokken is een duidelijk 
antwoord op deze vraag van belang. Dit kan belangrijke gevolgen hebben voor 
de vaccinatiegraad.
Gedurende de eerste week na de vaccinatie noteerden de deelnemers aan de 
trial klachten op de plaats van de prik, griepachtige klachten en astmaklachten 
en tevens medicatiegebruik, gezondheidszorggebruik en afwezigheid. Conform 
eerdere studies rapporteerden de deelnemers die het echte vaccin ontvingen veel 
vaker roodheid en een stijve arm dan zij die met placebo gevaccineerd waren. 
Wat betreft griepachtige symptomen waren er kleinere maar wel significante 
verschillen, ten voordele van de placebogevaccineerden, voor koorts, hoofdpijn 
en spierpijn in het eerste seizoen en heesheid in het tweede seizoen. Het verschil 
tussen de seizoenen zou te maken kunnen hebben met het verschil tussen de in 
het vaccin gebruikte stammen gedurende de twee seizoenen, maar kan ook een 
gevolg zijn van een verschil tussen de in de twee seizoenen deelnemende kinderen. 
Behalve een verschil voor hoesten overdag in het eerste seizoen ten voordele van de 
placebogevaccineerden waren er geen aanwijzingen dat vaccinatie astma-aanvallen 
uitlokte. Onze conclusie is daarom dat griepvaccinatie geen astma-aanvallen lijkt 
uit te lokken en veilig toegediend kan worden aan kinderen met astma.
In de wetenschappelijke literatuur is er weinig bewijs dat griepvaccinatie astma-
aanvallen voorkómt. In hoofdstuk 4 doen we verslag van de belangrijkste resultaten 
van ons gerandomiseerde dubbelblinde placebogecontroleerde onderzoek bij 
kinderen met astma naar het effect van influenzavaccinatie, waarbij we in het 
bijzonder naar astma-aanvallen keken.
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De deelnemende kinderen noteerden, zoals hiervoor beschreven, luchtwegklachten 
in een dagboekje. Als de gescoorde luchtwegklachten een van tevoren afgesproken 
grens bereikten, werd een keelwat afgenomen. Onze primaire uitkomstmaat 
was het aantal astma-aanvallen dat in verband gebracht kon worden met een 
virologisch bewezen influenza-infectie. We beschouwden een reductie van tenminste 
50% van het aantal astma-aanvallen als klinisch relevant. Van de deelnemende 
kinderen ontvingen 349 het placebovaccin en 347 het influenzavaccin. Van de 
gerapporteerde astma-aanvallen waren er 42 gerelateerd aan een influenzapositieve 
keelwat, 24 in de gevaccineerde groep en 18 in de placebogroep. Een verschil van 
33% ten voordele van de placebogroep (31% na correctie voor ‘confounders’; 
95% betrouwbaarheidsinterval –34% tot 161%). Influenzagerelateerde astma-
aanvallen waren even ernstig in beide groepen; ze duurden 3,1 dag korter in de 
vaccingroep (95% betrouwbaarheidsinterval, –6,2 tot –0,002 dag, p=0,06). Onze 
conclusie is dat influenzavaccinatie niet resulteerde in een significante vermindering 
van het aantal, de ernst en de duur van influenzagerelateerde astma-aanvallen. 
We zijn van mening dat aanvullende studies, waarbij ziekte in combinatie met 
bewijs voor influenza als eindpunt gebruikt wordt, noodzakelijk zijn om het 
jaarlijks vaccineren van kinderen met astma te rechtvaardigen.
Gezondheidsgerelateerde kwaliteit van leven (op lichamelijk, sociaal en emotioneel 
vlak) zou een belangrijke maat moeten zijn bij de evaluatie van de bewaking en 
controle van patiënten met astma.
In hoofdstuk 5 wordt de validering beschreven van de Nederlandse vertaling van 
de Engelstalige “Pediatric Asthma Quality of Life Questionnaire” (PAQLQ). 
We stelden de psychometrische eigenschappen, de responsiviteit, en de longitudinale 
en cross-sectionele constructvaliditeit van de Nederlandstalige PAQLQ vast. De 
bestudeerde groep bestond uit 238 kinderen (6-18 jaar) met astma, bestaande 
uit kinderen uit de trial naar het effect van griepvaccinatie, die een compleet 
dagboek met luchtwegsymptomen hadden ingevuld. Ieder kind onderging één 
(of meer) PAQLQ-meting(en) betreffende één of meer weken met betrekkelijk 
veel symptomen (n=238). Ieder kind beschikte ook over een PAQLQ-meting 
betreffende een week met betrekkelijk weinig symptomen. De PAQLQ-scores 
van deze weken werden vergeleken. Daarnaast vergeleken we een subgroep van 
kinderen met twee of meer weken met veel symptomen (n=101), we vergeleken 
de PAQLQ-scores van twee verschillende weken met veel symptomen van deze 
kinderen. De Cronbachs α’s van de totale score en de domeinscores waren allen 
groter dan 0,70, behalve voor het domein activiteiten (α=0,54). Dit geeft aan 
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dat de interne consistentie van de vragen in de vragenlijst matig tot goed is. De 
gemiddelde PAQLQ-scores verschilden significant (p <0,01; n=238) tussen een 
week met weinig en een week met veel symptomen. Daarentegen verschilden in 
de subgroep van kinderen met PAQLQ-metingen die meer dan één week met 
veel symptomen hadden (n=101) de gemiddelde PAQLQ-scores niet significant 
(p ≥0,05) tussen de ene en de andere week met veel symptomen. Deze resultaten 
zijn een aanwijzing voor de responsiviteit van de vragenlijst. Veranderingen in de 
scores van lagere luchtwegsymptomen, een aanwijzing voor de ernst van het astma, 
kwamen beter overeen met veranderingen in de PAQLQ-scores dan veranderingen 
in de scores van hogere luchtwegsymptomen. Dit ondersteunt de longitudinale en 
cross-sectionele constructvaliditeit van de PAQLQ. De vastgestelde eigenschappen 
van de Nederlandse vertaling van de PAQLQ waren gelijk aan de geconstateerde 
eigenschappen van de oorspronkelijke Canadese versie. Deze studie laat zien dat 
de Nederlandstalige PAQLQ adequate psychometrische eigenschappen heeft, 
een uitstekende responsiviteit bezit, en tevens wordt de longitudinale en cross-
sectionele constructvaliditeit onderbouwd. Omdat deze vragenlijst inmiddels in 
verschillende talen is vertaald en gevalideerd, is het een uitstekend instrument 
voor internationaal en transcultureel astma-onderzoek.
In hoofdstuk 6 laten we het effect van griepvaccinatie op het welbevinden van 
kinderen met astma zien.
Gebruik makend van de PAQLQ maten we het effect van griepvaccinatie op 
het fysieke, emotionele en sociale vlak bij astmatische kinderen. Daarnaast 
stelden we vast of griepvaccinatie een effect had op de met de PAQLQ-metingen 
corresponderende luchtwegklachten en spirometrische parameters en tevens op 
ál hun symptomen gedurende het seizoen.
Vergeleken met placebo verbeterde vaccinatie de gezondheidgerelateerde kwaliteit 
van leven in weken waarin de kinderen klachten hadden én de keelwat positief 
bleek voor influenza. Er werd echter geen effect gevonden wanneer we keken 
naar de luchtwegsymptomen die in die weken in het dagboek gescoord werden. 
Evenzeer vonden we geen verschil in kwaliteit van leven wanneer we alle weken 
met ziekte of luchtwegklachten over de seizoenen heen vergeleken.
Onze conclusie luidt dat influenzavaccinatie een gematigd positief effect heeft op 
de kwaliteit van leven in influenza-positieve weken bij kinderen met astma.
In hoofdstuk 7 beschouwen we onze bevindingen en komen tot de slotsom 
dat, gegeven de beschikbare informatie met betrekking tot de effectiviteit van 
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luchtwegmedicatie; de lage gemiddelde incidentie van influenza; de afwezigheid 
van direct bewijs voor de klinische effectiviteit van influenzavaccinatie bij kinderen 
met astma; de afwezigheid van ernstige bijwerkingen van griepvaccinatie en de 
twijfels over de kosteneffectiviteit van deze preventieve interventie bij astmatische 
kinderen, de richtlijnen met betrekking tot griepvaccinatie zouden moeten worden 
herzien en men, ondanks de veiligheid van de vaccinatie, het advies kinderen met 
matig tot ernstig astma te vaccineren zou moeten heroverwegen.
Toekomstig onderzoek zou zich als eerste moeten richten op lange termijn 
observationeel onderzoek en meerdere seizoenen moeten omvatten om de 
werkelijke weerslag van influenza bij kinderen met en zonder astma vast te stellen. 
Terwijl peilstations nu, in samenwerking met nationale influenzacentra, informatie 
verschaffen over het aantal griepachtige ziekten per aantal artscontacten of op 
het niveau van de algehele bevolking, zouden ze ook informatie kunnen leveren 
gestoeld op door kweek bewezen ziekte ten gevolge van influenza en over de 
ziektelast van influenza in een goed gedefinieerde populatie ‘at risk’.
Ten tweede zouden experimenten het effect kunnen meten van griepvaccinatie in 
verschillende leeftijds- en ziektegroepen, waaronder astma, waarvoor vaccinatie 
wordt geadviseerd maar waarvoor onvoldoende bewijs voorhanden is, waarbij de 
door peilstations gedekte bevolking in een bepaalde regio gevraagd zou kunnen 
worden mee te doen aan vaccinatieonderzoek. In ieder geval zouden studies zo 
moeten worden opgezet dat symptomen van patiënten op individueel niveau, en 
op symptomen gebaseerde metingen, zoals de PAQLQ, als uitkomstmaat worden 
genomen. Op deze wijze wordt aanpassing van de aanbevelingen geleid door op 
geneeskunde gestoeld bewijs, hetgeen de doeltreffendheid van de aanbevelingen 
kan verbeteren.
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